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ABSTRACT
Insulin-like growth factor-I (IGF-I) and its principle binding protein (IGFBP-3) are
believed to play a role in mediating the anabolic effects of exercise. The purpose of this
study was to assess the effect of 4 months of training on IGF-I and IGFBP-3, and to
determine if changes in IGF-I or IGFBP-3 were related to changes in training status.
Twelve varsity swimmers (5 males, 7 females) were tested pre-season, and again after 8
and 16 weeks of training. Measures included: VO2 max, nutritional status, athletic
performance, subjective symptoms of overtraining, and serum levels of IGF-I and
IGFBP-3. There was no significant change across time in VO2 max, athletic performance,
IGF-I or IGFBP-3. Resting IGFBP-3 was positively correlated to symptoms of
overtraining at week 0 (p=0.017), however, this relationship did not persist at week 8 or
16. These findings can not confirm that resting levels of IGF-I and IGFBP-3 are sensitive
markers of training status.
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1CHAPTER 1
INTRODUCTION
The Insulin-like growth factor (IGF) system is involved in a wide range of physiological
processes within the human body. IGF-I is an anabolic and mitogenic peptide that plays
an essential role in the regulation of somatic growth, development and metabolic
processes (Daughaday & Rotwein, 1989; Fargo & Chowen, 2005). According to the
somatomedin hypothesis, the anabolic and growth-promoting effects of growth hormone
(GH) are mediated through IGF-I (Eliakim, Nemet & Cooper, 2005; LeRoith, Bondy,
Yakar, Liu & Butler, 2001). IGF-I is also thought to be involved in the regulation of GH
production via a negative feedback with the hypothalamus (Berelowitz et al., 1981;
Daughaday, 2000).
Only a small fraction (<1%) of free IGF-I exists in human circulation, and the
majority (>99%) of IGF-I circulates bound to one of six binding proteins (IGFBP 1-6)
(Cohick & Clemmons, 1993). More than 75% of IGF-I circulates as part of a ternary
complex consisting of IGFBP-3 and an acid-labile subunit (ALS) (Baxter, 1994). IGFBP-
3 is produced primarily in the liver and is believed to be regulated by GH (Blum et al.,
1990; Martin & Baxter, 1992). In a study conducted by Baxter and Martin (1986) it was
observed that IGFBP-3 was 80% lower in GH deficient individuals and significantly
elevated in patients with excessive GH production (acromegaly).
IGFBPs play essential physiological roles within the human body. When IGF-I
binds with IGFBP-3 its half-life is prolonged at least 10-fold to 15-20 hrs (Martin &
Baxter, 1992), thus creating a large reservoir of circulating IGF-I (Juul et al., 1994). This
2bound IGF-I may become available during certain conditions, such as physiological stress
(Jones & Clemmons, 1995). IGFBP-3 also plays a critical role in regulating IGF-I
bioavailability. IGFBP-3 has a higher affinity for IGF-I than does the IGF-I receptor,
therefore, when IGF-I is bound to IGFBP-3 it cannot interact with the receptor (Jones &
Clemmons, 1995). In contrast to this obvious inhibitory role, it is hypothesized that
IGFBP-3 may also augment the action of IGF-I due to its association with specific
molecules located on the cell membrane. The association with these molecules results in
an increase in the local concentration of IGF-I in the vicinity of IGF-I receptors (Jones &
Clemmons, 1995).
IGF-I receptors are the only receptors that specifically recognize IGF-I and are
present in the majority of tissues within the body. IGF-I receptors are critical in
mediating the short-term metabolic and long-term mitogenic effects of IGF-I (Cohick &
Clemmons, 1993). Regulation of the IGF-I receptor is not well understood, however, it is
suggested that the number of IGF-I receptors is influenced by IGF-I concentration
(Poretsky, Glover, Laumas, Kalin & Dunaif, 1988).
Originally, IGF-I was thought to be primarily of hepatic origin and, therefore to
function solely in an endocrine manner. Advancements in technology have led to the
discovery of locally produced IGF-I, with autocrine/paracrine functions. It is believed the
production of hepatic IGF-I is under the control of GH (Clemmons & Van Wyk, 1984;
Daughaday & Rotwein, 1989; Deschenes, Kraemer, Maresh & Crivello, 1991), while the
production of non-hepatic IGF-I appears to be less sensitive to GH concentration (Muller,
Locatelli & Cocchi, 1999). It is unclear whether locally produced (non-hepatic) IGF-I
3contributes to circulating levels or if it is consumed by the tissue of origin (Eliakim,
Youngman & Cooper, 2000).
Circulating levels of IGF-I and IGFBP-3 show little daily variation (Gram et al.,
2006), however, their concentrations can be influenced by a number of genetic and
environmental factors. Both IGF-I and IGFBP-3 show a steady age-dependent effect,
peaking in the pubertal years and then declining throughout adult life (Baxter & Martin,
1986; Blum & Ranke, 1991; Hall et al., 1980; Harrela et al., 1996; Juul et al., 1994). This
observed decline is believed to be associated with the age-related decline in GH and
possibly a decrease in GH sensitivity (Juul et al., 1994), however, this relationship is not
fully understood. It is also suggested that the age related decline may be related to a
decline in physical activity (Kelly et al., 1990; Poehlman & Copeland, 1990).
Nutritional status is a well-known regulator of the IGF system. Prolonged fasting
in humans results in a significant decline in serum levels of IGF-I and IGFBP-3
(McCusker, Campion, Jones & Clemmons, 1989; Merimee, Zapf & Froesch, 1982;
Nemet et al., 2004; Thissen, Ketelslegers & Underwood, 1994). In contrast, overfeeding
leads to an increase in IGF-I levels (Forbes, Brown, Welle & Underwood, 1989). Total
energy intake and protein intake are reported to have a greater impact on IGF-I levels
compared to other components of diet (Cappon, Brasel, Mohan & Cooper, 1994).
The influence of body composition on the IGF system is not well documented.
However, recent findings suggest that both body mass index (BMI) and percent body fat
(%BF) are independent predictors of IGF-I concentration (Gomez et al., 2004; Gram et
al., 2006; Poehlman & Copeland, 1990). IGF-I and IGFBP-3 appear to be positively
related to BMI until a certain threshold is met (BMI = 24-26 kg/m
2
). When BMI
4surpasses this threshold, an inverse relationship is observed (Gram et al., 2006). In
addition, it was reported that male individuals who were classified as obese had lower
levels of IGF-I compared to non-obese individuals
(Gomez et al., 2004).
There is accumulating evidence that suggests exercise is a major regulator of both
IGF-I and IGFBP-3 concentrations. Previous studies have found circulating IGF-I to be
positively related to physical activity (Kelly et al., 1990; Poehlman & Copeland, 1990;
Rudman, 1985), aerobic fitness (Kelly et al., 1990; Manetta et al., 2003; Poehlman &
Copeland, 1990; Weltman et al., 1994) and muscular strength (Cappola, Bandeen-Roche,
Wand & Fried, 2001). However, since exercise can vary widely in mode, duration and
intensity, the effects of exercise on IGF-I and IGFBP-3 have been difficult to identify.
Several studies have confirmed that brief bouts of intense aerobic exercise results
in transient increases in IGF-I (Bang et al., 1990; Copeland & Heggie, (in press); Dall et
al., 2001; Elloumi et al., 2005; Schwarz, Brasel, Hintz, Mohan & Cooper, 1996). The
mechanisms responsible for the exercise-induced increase have not been clearly
established. In contrast to the observed increase, other studies have revealed no change or
slightly decreased IGF-I levels following prolonged endurance exercise (Koistinen,
Koistinen, Selenius, Yikorkala, Seppala, 1996; Suikkari et al., 1989; Wilson & Horowitz,
1987). It is believed that an exercise-induced decrease in IGF-I may reflect energy
availability. Prolonged exercise (2-3 hours) can lead to an energy deficient state and
depleted glycogen stores and previous work has confirmed that energy deficiency can
lead to a decrease in circulating IGF-I (Nemet et al., 2004; Smith, Clemmons,
Underwood, BenEzra & McMurray 1987). A number of other factors such as exercise
5intensity, training status and subject age may also influence exercise-induced energy
deficiency and subsequent decline in IGF-I concentration.
Acute exercise may also have transient effects on circulating levels of IGFBP-3.
Studies have found IGFBP-3 to increase following acute exercise (Chadan et al., 1999;
Copeland & Heggie, (in press); Schwarz et al., 1996). The findings from both Schwarz et
al. (1996) and Copeland and Heggie (in press) suggest the IGFBP-3 response may be
intensity dependent. Conversely, other studies have found no change or a decrease in
IGFBP-3 concentration following acute exercise (Koistinen et al., 1996). Similar to IGF-
I, it is speculated that exercise duration may have a significant influence on the IGFBP-3
response to acute exercise.
Findings from a recent study suggest that a relationship between training status
and IGFBP-3 concentration exists. Elloumi et al. (2005) reported that fatigued and
potentially overtrained athletes, as estimated by scores on an overtraining questionnaire,
present a decrease in IGFBP-3 level in response to acute exercise. Elloumi et al. (2005)
did not provide any physical measures of training status or a longitudinal examination of
this potential relationship. Confirming and understanding the relationship between
training status and IGFBP-3 may help in developing an effective tool for diagnosing
overtraining training syndrome (OTS).
The effect of long-term training on the IGF-I system is not well understood. Some
studies have indicated an increase in resting IGF-I following exercise training (Chicharro
et al., 2001; Koziris et al., 1999; Poehlman, Rosen and Copeland, 1994; Roelen et al.,
1997), while others have reported a decrease (Eliakim, Brasel, Mohan, Wong & Cooper,
1998; Eliakim et al., 1996; Jahreis, Kauf, Frohner & Schmidt, 1991; Rosendal et al.,
62002). The inconsistencies among results may be explained by various factors, including
age, nutritional status and intensity of training. Recent findings from Rosendal et al.
(2002) suggest that training experience or fitness is one factor that has a significant
influence on resting IGF-I. It was found that 11-weeks of exercise training lead to
decease in resting IGF-I within the untrained subjects, where as no change in resting IGF-
I was found within the trained subjects.
Long-term exercise training may also influence resting levels of IGFBP-3. Studies
have found IGFBP-3 to increase in response to six-months of high volume swim training
(Koziris et al., 1999) and following four months of intense cycling training (Manetta et
al., 2003). In contrast, no significant change in IGFBP-3 was detected following eight
weeks of endurance training (Poehlman, Rosen, and Copeland, 1994), three weeks of
cycling training (Chicharro et al., 2001), and eight months of triathlon training (Maimoun
et al., 2004). Moreover, IGFBP-3 has also been found to decrease in response to five
weeks of exercise training (Eliakim et al., 1996; Eliakim et al., 1998) and four weeks of
military training.
It has been hypothesized that the effects of exercise training on resting levels of
IGFBP-3 are dependent on the relative physiological stress applied during exercise
training (Rosendal et al., 2002). If the physiological stress during exercise training
exceeds a certain minimum threshold, IGFBP-3 levels are expected to increase.
Conversely, if the physiological stress during training exceeds a maximum threshold,
IGFBP-3 levels are expected to decrease (Rosendal et al., 2002). Although the magnitude
of physiological stress needed to surpass the minimum and maximum thresholds is
7unique to the individual and dependent on various factors, training status appears to be
highly correlated with these thresholds (Rosendal et al., 2002).
PURPOSE OF THE STUDY
Numerous studies have investigated the response of IGF-I and IGFBP-3 to acute
exercise, however, the response of IGF-I and IGFBP-3 to exercise training remains
poorly documented. Studies have suggested that acute changes in IGF-I and IGFBP-3 can
provide an indication of training status, however, this has not been examined over the
course of a long-term training period. Therefore, the purpose of this study is to assess the
effects of long-term exercise training on the resting levels of IGF-I and IGFBP-3 and to
determine if changes in resting IGF-I or IGFBP-3 are associated with measures of
training status including maximal aerobic power, athletic performance or symptoms of
overtraining.
SIGNIFICANCE
An understanding of how training status, and potentially overtraining, affects
resting IGF-I and IGFBP-3 would assist athletic trainers, coaches and athletes in
identifying optimal training volumes. Understanding this relationship could also be
beneficial for elite athletes as it may allow early detection of overtraining syndrome
(OTS) so that appropriate preventive measures can be taken.
8HYPOTHESES
1. Resting levels of IGF-I and IGFBP-3 will increase with increased fitness and athletic
performance.
2. If an individual exhibits symptoms of overtraining, resting levels of IGFBP-3 will
decrease.
LIMITATIONS AND DELIMITATIONS
Limitations
1. It was assumed that subjects completed the health screening form accurately and
therefore were free from medications that could affect hormone concentration.
2. It was assumed that subjects truthfully and accurately recorded their food records
and therefore accurately portrayed their nutritional status.
3. It was assumed that subjects correctly answered the SFMS questionnaire and
therefore accurately portrayed their subjective training status.
4. It was assumed that subjects followed the specified pre-testing guidelines before
blood samples were drawn and before fitness testing.
5. Motivation of subjects is subjective and may have varied between testing
sessions.
Delimitations
1. The sample was limited to 5 male and 7 females who were all members of the
University of Lethbridge swim team, therefore, these results may only be
generalized to young male and female varsity swimmers.
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REVIEW OF THE LITERATURE
The Insulin-Like Growth Factor (IGF) system plays a critical role in normal
growth and development in the human body (LeRoith, Scaveo & Butler, 2001a; LeRoith,
Bondy, Yakar, Lui & Butler, 2001b). In addition to growth and development, the IGF
system also participates in cell differentiation and survival, metabolic processes and
tissue repair (Baker, Liu, Robertson & Efstratiadis, 1993; Daughaday & Rotwein, 1989;
Liu, Baker, Perkins, Robertson and Efstratiadis, 1993). The IGF system consists of IGF-I
and IGF–II, IGF-binding proteins (IGFBP) 1-6, acid-labile subunit (ALS), IGF receptors
(IGF-R) and IGFBP protease (Butler & LeRoith, 2001).
The Insulin-like Growth Factors (IGF-I and IGF –II) are single chain polypeptide
growth factors (Cohick & Clemmons, 1993). IGF-I is a 70-amino acid polypeptide,
which plays a significant role in the growth of most, if not all, tissues in the body
(Kraemer, 1994). IGF-II is a 67-amino acid polypeptide, which is thought to play a
significant role in prenatal development, however, its physiological significance is less
understood. Due to the limited knowledge surrounding the function of IGF-II and its
response to exercise, this review will focus on IGF-I.
The amino acid sequence of IGF-I shares approximately 50% homology with
insulin (Rinderknecht & Humbel, 1978a; Rinderknecht & Humbel 1978b). Unlike
insulin, IGF-I circulates in the blood at a total concentration of 0.1 umol/L, which is 1000
times greater than the circulating insulin concentration (Mohan & Baylink, 1996). The
liver is the primary source of IGF production and secretion (Deschenes et al., 1991),
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however, it is now clearly established that IGF-I is also produced in many other tissues
including bone, skeletal muscle, kidney, adipose, pancreas, and skin (Daughaday &
Rotwein, 1989; D’Ercole, Applewhite & Underwood, 1980; LeRoith & Roberts, 1993;
Muller et al., 1999; Van, Lund, Lee & D’Ercole, 1988). Within human muscle, two
variants of IGF-I have been identified, IGF-IEa and IGF-IEc, also known as ‘mechano
growth factor’ (MGF). IGF-IEa is produced in muscle and is thought to play a role in
upregulating protein synthesis.  It is believed that IGF-IEa is similar to hepatic IGF-I in
that it has an endocrine function (Goldspink & Harridge, 2004). MGF is thought to be
regulated by physical activity and, unlike IGF-IEa, MGF is potentially consumed by the
muscle, indicating a paracrine action (Goldspink & Harridge, 2004). The role of these
muscle-produced growth factors is not fully understood, and how much they contribute to
circulating concentration of IGF-I or consumed by the muscle is unknown. Few studies
have investigated the production of muscular IGF-I and other non-hepatic IGF-I because
of the difficulty in quantifying their concentrations.
Growth Hormone (GH) is believed to be the major hormonal regulator of hepatic
IGF-I (Clemmons & Van Wyk, 1984; Daughaday & Rotwein, 1989; Deschenes et al.,
1991). Studies have shown that the administration of GH to normal healthy subjects
results in a significant increase in plasma IGF-I concentrations (Copeland, Underwood &
Van Wyk, 1980). Conversely, locally produced IGF-I is thought to be under the influence
of different regulators depending on the tissue type (Muller et al., 1999). For example, it
has been shown that in cortical bone, sex steroids, GH, and parathyroid hormones
regulate IGF-I production, while in the reproductive system, IGF-I is thought to be under
the influence of sex steroids (Muller et al., 1999).
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The majority (more than 75%) of circulating IGF-I is bound to a 150 kDa ternary
complex consisting of IGFBP-3 and an acid labile subunit (Cohick & Clemmons, 1993).
IGF-I exerts its effect at the cellular level by interacting with an IGF-I receptor (IGF-IR)
(Cohick & Clemmons, 1993). Originally it was thought IGF-I interacted with IGF
receptors solely in an endocrine manner, however, it is now recognized that locally
produced IGF-I acts in an autocrine-paracrine manner (LeRoith & Roberts, 1993).
SOMATOMEDIN HYPOTHESIS
The existence of IGFs was first proposed in 1957 (Salmon & Daughaday, 1957).
At that time, researchers were trying to understand the interactions between pituitary
hormones and somatic growth. Salmon and Daughaday (1957) revealed that when the
anterior pituitary of the rat was surgically removed (hypophysectomy) a reduction in the
incorporation of sulfate (SO4) into chondroitin sulfate of epiphyseal cartilage resulted.
When these same rats were treated with bovine growth hormone (bGH) the incorporation
of sulfate into cartilage was greatly renewed, however, when bGH was injected into
cartilage prepared in vitro, minimal results were observed. These findings illustrated that
GH alone does not stimulate growth directly, but rather it acts indirectly through a serum
factor.
Due to its ability to stimulate the uptake of sulfate into epiphyseal cartilage, this
newly discovered serum factor was labeled sulfation factor (LeRoith et al., 2001b).
However, in the 1970’s, sulfation factor was renamed to somatomedin to reflect its ability
to mediate the effects of GH (Daughaday et al., 1972; Jones & Clemmons, 1995). After
the establishment of its primary amino acid sequence (Rinderknecht & Humbel, 1978a;
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Rinderknecht & Humbel 1978b), and the discovery of its ability to stimulate glucose
uptake into fat and muscle cells (Froesch et al., 1976; Rinderknecht & Humbel, 1978a),
the somatomedins were renamed to insulin-like growth factor-I and II.
At the time of discovery, different hypotheses were developed to model the
growth promoting actions of IGF-I, however, the somatomedin hypothesis was the most
widely accepted (LeRoith et al., 2001b). The original somatomedin hypothesis proposed
that GH secreted from the anterior pituitary stimulated the production and secretion of
IGF-I from the liver (Fig. 1) and then, via endocrine action, IGF-I would stimulate
epiphyseal plate cartilage and longitudinal bone growth (LeRoith et al., 2001b).
This original somatomedin hypothesis was challenged when D’Ercole et al.
(1980) found that IGF-I was produced and released by many other tissues in the body, not
solely the liver. From their findings it was suggested that IGF-I had an autocrine-
paracrine function as well as the classic endocrine function (LeRoith et al., 2001a). Also
challenging the original hypothesis was the work by Berelowitz et al. (1981), who found
that circulating IGF-I acted on the anterior pituitary via a negative feedback loop,
therefore, regulating the release of GH. These new findings led to a revision of the
original somatomedin hypothesis (Fig. 1).
13
                
Figure 1. Original Somatomedin Hypothesis and the later revised Somatomedin
Hypothesis. (Adopted from LeRoith et al. (2001b), with permission).
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PHYSIOLOGICAL ROLE OF THE GH/IGF AXIS
Growth Hormone (GH) Action
Evans and colleagues discovered GH in 1921 when they found that extract from
the anterior pituitary promoted physical growth and maturation (Fargo & Chowen, 2005).
GH is a peptide hormone synthesized in the anterior pituitary, which is regulated by two
neuropeptide hormones from the hypothalamus. Growth hormone-releasing hormone
(GHRH) stimulates GH release and somatostatin (SS) inhibits GH release (Daughaday,
2000; Fargo & Chowen, 2005). GH is secreted in a pulsatile manner, with 6 to 8 bursts
per day (Borst, Millard & Lowenthal, 1994). The highest plasma concentration of GH is
detected during the rapid eye movement (REM) phase of the sleep cycle, with elevations
also observed 3 to 4 hours after a meal (Corpas, Harman & Blackman, 1994). The lowest
levels of plasma GH occur in the morning (Corpas et al., 1994).
The name “growth hormone” was coined due to its stimulation of physical growth
of the body (Friedl, 1994). GH has been shown to play a role in the growth of bone,
connective, adipose, visceral and muscle tissue (Hedge, Colby & Goodman, 1987). It is
interesting to note that GH effects occur primarily postnatally and is not considered to be
critical in prenatal growth. In support, Laron (1993) reported that infants diagnosed with
GH deficiency (GHD) or GH receptor deficiencies are born of normal stature. In addition
to its function in stimulating growth, GH is also thought to have a metabolic function,
including the maintenance of blood glucose, protein synthesis and lipid metabolism
(Fargo & Chowen, 2005; Muller et al. 1999).
IGF-I has long been regarded as the mediator of the effects of GH (Wang, Zhou,
Cheng, Kopchick & Bondy, 2004) and whether or not GH can act independently of IGF-I
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has been greatly debated. More evidence is now suggesting GH does have IGF-I
independent effects on somatic growth (Hunziker, Wagner & Zapf, 1994; Ohlsson,
Nilsson, Isaksson & Lindahl, 1992; Ueland, 2005). Wang et al. (2004) found that long
bone growth in rats was more profoundly affected in the absence of GH (no GH and
decreased IGF-I) compared to the absence of IGF-I (no IGF-I but elevated GH),
therefore, suggesting that GH may have a direct effect on longitudinal bone growth.
Although some studies suggest that GH has direct effects, more research is needed to
confirm this theory.
Insulin-like Growth Factor (IGF) Action
IGF-I is polypeptide hormone that regulates cell growth and development as well
as cell replication and differentiation (Jones & Clemmons, 1995). The actions of IGF-I
are mediated primarily by interactions with type I IGF receptors (IGF-IR). IGF-I
circulates bound to a family of six binding proteins, which is believed to regulate its
endocrine actions (Paye & Forsten-Williams, 2006). IGF-I receptors are expressed on the
majority of tissues in the body, thus indicating the widespread importance of IGF-I
(LeRoith, Werner, Beitner Johnson & Roberts, 1995).
Growth and Development
Proliferation (mitogenesis) and differentiation (myogenesis) are complex
processes that are influenced by a number of mitogenic growth factors. The majority of
growth factors stimulate proliferation, but inhibit differentiation. IGF-I is unique among
growth factors as it stimulates both proliferation and differentiation in skeletal-muscle
cells (Quinn, Steinmetz, Mass, Ong & Kaleko, 1994). The role of IGF-I in the promotion
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of proliferation and differentiation has been extensively reviewed by Florini and
colleagues (Florini et al., 1984; Florini, Ewton & Coolican, 1996).
IGF-I’s involvement in skeletal-muscle growth and development is most
strikingly demonstrated within studies using animal lines lacking the components of IGF
system (knockout experiments). Mice lacking IGF-I expression and/or IGF-I receptors
are significantly smaller than their littermates and experience severe muscular dystrophy
and the majority die immediately following birth (Lui, Baker, Perkins, Robertson and
Efstratiadis, 1993; Powell-Braxton et al., 1993). It is believed that IGF-I plays a critical
role in the expression of a muscle cell-specific transcription factor, myogenin. In support
of this theory, mice lacking the expression of myogenin are also born with severe
muscular dystrophy (Florini et al., 1996). Studies have also demonstrated that transgenic
mice over-expressing IGF-I have enhanced muscle and bone growth (Levinovitz,
Jennische, Oldfors, Edwall & Norstedt, 1992; Mathews et al., 1988). To further
demonstrate the significance of IGF-I on growth, it has been shown that the
administration of IGF-I to growth deficient mice, leads to increase in body weight and
length (Gillespie, Read, Bagley & Ballard, 1990).
The effects of IGF-I on growth and development within humans have also been
described. In cases where IGF-I is significantly decreased as in GH deficiency (GHD),
physical growth is suppressed. In contrast, elevated levels of IGF-I as in acromegaly,
results in excessive growth (Baxter & Martin, 1986; Blum et al., 1990). The effects of
IGF-I on human growth and development are also apparent during puberty. A
relationship is seen during the peripubertal period when both IGF-I (LeRoith & Roberts,
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1993; Bennett, Wahner, Riggs & Hintz, 1984; Cohick & Clemmons, 1993), and physical
growth are significantly elevated.
Metabolic Function
Besides playing critical roles in physical growth and development, IGF-I also
exhibits a metabolic function. Since IGF-I is structurally homologous to insulin and can
interact with the insulin-receptor (IR), it is not surprising that IGF-I has the potential to
influence glucose metabolism (Hussain et al., 1993). Interestingly, IGF-I circulates in the
body at a concentration 1000 times greater than insulin (Daughaday & Rotwein, 1989),
therefore, IGF-I could theoretically contribute 50 times more insulin-like activity than
insulin itself (Mohan & Baylink, 1996). Fortunately, this does not occur because the
insulin-activity of IGF-I is largely neutralized as a consequence of binding to the IGFBPs
(Mohan & Baylink, 1996).
Guler, Zapf and Froesch (1987) were the first to confirm the metabolic actions of
IGF-I in healthy human subjects. They found that a single intravenous injection of IGF-I
induced a rapid onset of hypoglycemia. Turkalj, Keller, Ninnis, Vosmeer and Stauffacher
(1992) indicated similar findings, but also concluded that the insulin-like actions of IGF-I
were dose dependent, thus, as the dose of IGF-I increased, so did the rate of glucose
metabolism. The Insulin-like effects of IGF-I have also been detected in patients
diagnosed with chronic illness, such as type I & II diabetes (Holt, Simpson & Sonksen,
2003), and Laron dwarfism (Laron, Klinger, Erster & Anin, 1988).
Insulin-like Growth Factor Binding Proteins (IGFBP)
Zapf and colleagues were the first to discover the existence of IGFBPs (Zapf,
Waldvogel & Froesch, 1975). Today, six structurally distinct high-affinity IGFBPs (1-6)
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have been identified (Mohan & Baylink, 2002). Of these six binding proteins, IGFBP-3 is
the most abundant in human serum (Ferry, Katz, Grimberg, Cohen & Weinzimer, 1999;
Martin & Baxter, 1992). Approximately 75% of IGF-I circulates as part of a larger
ternary complex, which consists of IGFBP-3 and a non-IGF binding component termed
acid-labile subunit (ALS) (Jones and Clemmons, 1995). The majority of IGFBP-3 and
ALS is produced in the liver, however, IGFBP-3 is also produced in a number of other
tissues including skeletal muscle, the spleen, heart and prostate (Baxter, 1994; Mohan &
Baylink, 2002).
It is proposed that along with IGF-I, IGFBP-3 production is also under hormonal
control, most notably by GH, however, the mechanism by which GH stimulates IGFBP-3
production is still under investigation. In a study conducted by Baxter and Martin (1986)
it was observed that IGFBP-3 was 80% lower in GH deficient patients and was later
observed to be significantly elevated in acromegalic patients. Studies have also indicated
other factors such as glucocorticoids (Conover, Clarkson & Bale, 1995), estradiol
(Huynh, Yang & Pollak, 1996), insulin (Suikkari et al., 1988), and prostaglandins
(DiBattista, Dore, Morin & Abribat, 1996) may influence IGFBP-3 production.
A common function among binding proteins in general is to regulate ligand
activity by prolonging its half-life (Mohan & Baylink, 2002). When an IGF-I binds with
an IGFBP-3 and an ALS, its half-life is prolonged at least 10-fold (15-20 hrs) (Martin &
Baxter, 1992), thus creating a large reservoir of IGF-I. These IGF-complexes remain in
circulation because IGF cannot cross the vascular endothelial barrier without being
reduced back to its free form (Binoux & Hossenlopp, 1988; Rajaram, Baylink & Mohan,
1997; Zapf, 1995). The exact function of the large stores of IGF-I is unknown, however,
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it is hypothesized that this bound IGF-I can be made available during certain
physiological conditions such as stress (Jones & Clemmons, 1995).
IGFBP-3 also plays a critical role in the regulation of IGF-I bioavailability, which
is the amount of IGF-I available to promote its biological action (Chadan et al., 1999). In
serum, IGFBP-3 has a higher affinity for IGF-I than does the IGF-I receptor, therefore,
inhibiting receptor interaction (Jones & Clemmons, 1995). Without receptor interaction,
the metabolic (Zapf et al., 1979) and growth promoting actions (Gillespie et al., 1990;
DeMello & Baxter, 1988) of IGF-I are inhibited. More recent evidence has shown that
IGFBP-3 can also express inhibitory effects independently of IGF-I. It has been
demonstrated that IGFBP-3 alone can inhibit the growth of breast cancer cells (Oh,
Muller, Lamson & Rosenfeld, 1993) and prostate cancer cells (Silha et al., 2006),
however, the mechanisms behind these actions are not fully understood.
In contrast to its inhibitory role, IGFBP-3 has been shown to augment the action
of IGF-I. Evidence of this action is apparent during the growth period of childhood and
puberty. During this time serum IGFBP-3 significantly increases, showing a positive
correlation with growth activity (Baxter, 1994). Moreover, it is also reported that the
growth restoration by GH therapy in GH deficiency is accompanied by an increase in
IGFBP-3 (Baxter, 1994). Research findings have also associated IGFBP-3 with
accelerated wound healing, tissue regeneration and bone growth (Hamon, Hunt &
Spencer, 1993; Mohan, 1994).
One proposed mechanism whereby IGFBP-3 potentiates IGF-I action is based on
its association with specific molecules located on the cell membrane. The association
with these molecules results in an increase in the local concentration of IGF-I in the
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vicinity of IGF-I receptors (Jones & Clemmons, 1995). The binding of the IGFBP-3 to a
surface molecule causes a decreased affinity for IGF-I, resulting in its release. This now
free IGF-I is able to bind with the IGF-I receptor, thus, its mitogenic and metabolic
actions can be expressed. Figure 2 illustrates the proposed mechanism whereby IGFBP-3
potentiates IGF-I action.
In summary, the exact role of IGFBP-3 is yet to be determined. It is clear that
IGFBP-3 plays a key role in regulating IGF-I action by inhibiting receptor interaction.
Conversely, IGFBP-3 may also promote the actions of IGF-I by prolonging its half-life
and transporting it closer to the IGF-I receptors. The role IGFBP-3 is likely dependent on
a number of factors including the developmental stage and/or physiological condition of
the individual.
Fig. 2. Proposed mechanism whereby IGFBP-3 potentiates IGF-I action
(Adopted from Jones & Clemmons, 1995, with permission).
21
IGFBP-Protease
As indicated in the preceding section, IGF-I must be released from its binding
protein in order to cross the endothelial barrier of the blood vessel and interact with an
IGF-I receptor. Several mechanisms have been shown to facilitate this process, however,
proteolytic cleavage via IGFBP-protease is the only method demonstrated for all IGFBPs
(1-6). Thus, IGFBP-protease is considered to be the predominate mechanism that serves
to increase IGF-I bioavailability (Bunn & Fowlkes, 2003; Frystyk, 2004).
IGFBP-protease are a group of proteolytic enzymes that are capable of cleaving
IGFBPs into smaller fragments with lower affinity for IGF-I, resulting in a reduced
ability to inhibit IGF-I action (Blat, Villaudy & Binoux, 1994; Katz, Rosenfeld & Cohen,
1995). Although IGFBP-protease activity may occur in the normal state (Lalou &
Binoux, 1993), it is considerably greater during physiological stress, such as pregnancy,
severe illness and exercise (Davenport et al., 1990; Giudice, Farrell, Pham, Lamson &
Rosenfeld, 1990; Hossenlopp et al., 1990; Jones & Clemmons, 1995).
IGF-I Receptors
Most of the biological actions of IGF-I are mediated by the IGF-I receptor (Fargo
& Chowen, 2005; Werner et al., 1991). IGF-I receptors have been detected in a wide
variety of tissues and cell lines and are the only receptor to specifically recognize IGF-I
(Cohick & Clemmons, 1993; Jones & Clemmons, 1995). Structurally, the IGF-I receptor
shares a high degree of homology (~70%) with the insulin receptor (Fargo & Chowen,
2005). It is not surprising that the IGF-I receptor will bind with insulin at
supraphysiological concentrations, although its affinity for insulin is approximately 100-
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to 500-fold lower compared to IGF-I (Werner et al., 1991). The IGF-receptor will also
bind with IGF-II, but once again its affinity is significantly reduced (Werner et al., 1991).
IGF-I receptors are capable of mediating short-term metabolic, long-term
mitogenic and antiapoptotic effects (Cohick & Clemmons, 1993), however, the
mechanisms behind these processes are complex and not entirely understood. It is
proposed that the binding of IGF-I with the IGF-I receptor causes the
autophosphorylation of the receptor, which in turn leads to an interaction with cellular
substrates, most notably insulin receptor substrate-I (IRS-I) (Fargo & Chowen, 2005).
This interaction then mediates the transmission of mitogenic and metabolic signals to the
cell nucleus (Cohick & Clemmons, 1993; Fargo & Chowen, 2005).
Research on animal and in-vitro models has indicated that regulation of the IGF-I
receptor appears to be dependent on the concentration of IGF-I (Poretsky et al., 1988).
Downregulation, a decrease in receptor number with increased IGF-I concentration, has
been detected in a number of these models (LeRoith & Roberts, 1993). Conversely,
upregulation, an increase in receptor number with a decrease in IGF-I concentration, has
also been confirmed (LeRoith & Roberts, 1993). Although the biological significance of
these processes is unclear, they may regulate the expression of IGF-I action when
fluctuations in circulating IGF-I or IGFBPs occur.
FACTORS INFLUENCING IGF-I AND IGFBP-3
Circulating levels of IGF-I and IGFBP-3 are remarkably stable. No obvious daily
variations have been observed (Blum & Ranke, 1991; Gram et al., 2006; Hall & Sara,
1984), however, serum levels are influenced by various factors.
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Effects of Age
Serum levels of IGF-I and IGFBP-3 exhibit a considerable age-dependent pattern.
At birth serum levels are low but gradually increase during childhood, before peaking in
the pubertal years (Hall et al., 1980). The temporary peak observed at the onset of
puberty occurs almost 2 years earlier in females than in males, paralleling their normal
pubertal development (Blum & Ranke, 1991). In adulthood, levels continuously decline
with increasing age (Baxter & Martin, 1986; Hall et al., 1980; Harrela et al., 1996; Juul et
al., 1994). In old age, serum levels are reported to be as low as those at birth (Hall &
Sara, 1984). It is believed that the decrease in IGF-I and IGFBP-3 levels are secondary to
an age-dependent decrease in GH production and or GH sensitivity (Hall & Sara, 1984;
Juul et al., 1994). Alternatively, others suggest that the age-related decline in serum IGF-I
is related to lifestyle change such as a decline in physical fitness (Kelly et al., 1990;
Poehlman & Copeland, 1990).
Effects of Body Composition
The relationship of IGF-I and IGFBP-3 with body composition is not well
understood. Since adiposity has been shown to be inversely related to GH secretion
(Rasmussen et al., 1995) and GH stimulates the hepatic production of IGF-I and IGFBP-
3, circulating levels of IGF-I and IGFBP-3 are expected to be low in obese subjects.
However, studies investigating IGF-I and IGFBP-3 levels in obese subjects have
produced conflicting results. Recently, Gram et al. (2006) reported a nonlinear
relationship between IGF-I and body mass index (BMI), which is in support of previous
findings (Lukanova et al., 2002; Lukanova et al., 2004). The highest levels of IGF-I were
found at a BMI between 24.6-26.6 kg/m
2
, while the lowest levels were detected in the
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extreme categories of BMI. A positive relationship between IGFBP-3 and obesity has
also been reported, however, when adjusted for waist to hip ratio (WHR), significance
was lost (Gram et al., 2006).
Effects of Nutrition
Nutritional status is a well-established regulator of the IGF-I system. Prolonged
dietary restriction has been shown to significantly decreases serum IGF-I (Clemmons et
al., 1981; Eliakim et al., 2005; Nemet et al., 2004; Smith et al., 1987) and IGFBP-3
(Axelsson et al., 2006; Frystyk et al., 2003; Thissen et al., 1994). It is unanimous among
researchers that protein and calorie intake have the greatest effects on IGF-I and IGFBP-3
levels when compared to other components of the diet.
Low levels of IGF-I and IGFBP-3 are not due to decreased GH concentration
since GH secretion is increased during caloric restriction (Thissen et al., 1994).
Alternatively, it is hypothesized that fasted individuals develop GH resistance and
therefore have decreased hepatic IGF-I production (Gram et al., 2006; Thissen et al.,
1994).
In contrast to the effects of prolonged fasting, a significant increase in IGF-I
occurs during prolonged overfeeding. Forbes et al. (1989) observed that 21 days of
overfeeding caused a significant increase in serum IGF-I. It is thought that the increase in
IGF-I level following overfeeding reflects an increase in insulin concentration (Thissen et
al., 1994).
Effects of Exercise
Exercise is an important regulator of both IGF-I and IGFBP-3 concentrations.
IGF-I has been shown to be positively related to physical activity (Kelly et al., 1990;
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Poehlman & Copeland, 1990; Rudman, 1985), aerobic fitness (Kelly et al., 1990; Manetta
et al., 2003; Poehlman & Copeland, 1990) and muscular strength (Cappola et al., 2001).
However, since exercise can vary widely in mode, duration and intensity, the effects of
acute exercise and exercise training on IGF-I and IGFBP-3 have been difficult to identify.
IGF-I Response to Acute Exercise
Acute bouts of aerobic exercise result in transient increases in circulating IGF-I.
Increases have been observed following 30 minutes of moderate-intensity exercise (Bang
et al., 1990), 20 minutes of continuous and intermittent exercise (Copeland & Heggie, in
press), 10 minutes of exercise below and above the lactate threshold (Schwarz et al.,
1996), and following a maximal test to exhaustion (Dall et al., 2001; Elias et al 2000).
Currently, the mechanism responsible for exercise-induced increases in IGF-I is
unknown. It is possible that the exercise-induced increase in IGF-I reflects an increase in
the production of hepatic IGF-I as a result of an exercise-induced increase in GH
(Eliakim et al., 2005). As discussed previously, GH is the major hormonal regulator of
IGF-I, however, more recent findings suggest that exercise-induced increase in IGF-I is
independent of circulating GH (Schwarz et al., 1996). It was found that GH increased
only after high-intensity exercise, although IGF-I increased in both high and low
intensities (Schwarz et al., 1996). In addition, other studies have reported increases in GH
after endurance exercise with no subsequent increase in IGF-I (Wilson & Horowitz,
1987).
It has also been proposed that the exercise-induced increase in IGF-I is due to an
increased influx from locally produced IGF-I (Brahm, Piehl-Aulin, Saltin, B & Ljunghall,
1997; Dall et al., 2001). The production and release of IGF-I from exercising muscle has
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been reported (Brahm et al., 1997), however, it is unknown if non-hepatic IGF-I
contributes to circulating levels. Eliakim et al. (2000) found that when blood was
simultaneously collected from the basilic vein of both an exercising and a resting arm, a
bilateral increase in IGF-I was detected in both arms, which suggests exercising muscle
was not the only source of the increase in circulating IGF-I.
Hemoconcentration may also be in part responsible for exercise-induced increases
in IGF-I (Cappon et al., 1994; Dall et al., 2001; Eliakim et al., 2000). It is acknowledged
that exercise can induce a rapid decrease in plasma volume. If this decrease in plasma
volume is not corrected for, an increase in IGF-I concentration may be detected, although
no absolute increase in IGF-I occurred (Dill & Costill, 1974). Dall et al. (2001) reported
an increase in IGF-I concentration in response to high intensity exercise, however, when
corrected for plasma volume, no significant change in IGF-I was found.
While the above studies all demonstrate an increase in IGF-I in response to
exercise, other studies have revealed no change or slightly decreased IGF-I levels after
acute bouts of endurance exercise (Kanaley et al., 2005; Koistinen et al., 1996; Smith,
Clemmons, Underwood, BenEzra & McMurray, 1987; Suikkari et al., 1989; Wilson &
Horowitz, 1987). Table 1 provides a summary of studies that have investigated the IGF-I
response to acute bouts of endurance exercise.
The variation among findings suggests that the IGF-I response to acute exercise is
influenced by a multitude of factors. Exercise intensity is one factor that may have an
influence on IGF-I. Several studies have found that acute bouts of intense exercise does
result in increased IGF-I level (Elloumi et al., 2005; Schwarz et al., 1996), while studies
utilizing lower intensities have found no significant increase in circulating IGF-I
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(Kanaley et al., 2005; Wilson & Horowitz, 1987). Thus, it is possible that an intensity
threshold must be met in order to stimulate an increase in circulating IGF-I. However, in
contrast to this apparent trend, Schwarz et al., (1996) found an increase in IGF-I at low
intensity exercise, which was similar to high-intensity exercise. This inconsistent finding
further confirms that multiple factors influence the IGF-I response to acute exercise.
Exercise duration also appears to impact the IGF-I response. It has been
acknowledged that when the energetic cost exceeds energy consumption, IGF-I levels
decrease (Koistinen et al., 1996; Nemet et al., 2004; Suikkari et al., 1989). It is believed
that during prolonged exercise, glucose stores become depleted and therefore
glycogenolysis and glucose transport have to be downregulated in the exercising muscle
and liver. At the same time liver production of IGF-I is thought to decrease because of
the insulin-like effects of IGF-I on the blood glucose concentration (Steinacker, Lormes,
Reissnecker & Liu, 2004). In agreement, previous investigations have found that IGF-I
concentration declines in response to an energy deficient state (Smith et al., 1987).
Although it is possible that the prolonged exercise duration in the studies conducted by
Koistinen and Suikkari may have led to a decrease in IGF-I, it is noted that a combination
of factors such as training status, age and nutritional status may have also had a
significant influence on the decline in IGF-I concentration.
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Table 1. Summary of studies examining the IGF-I response to acute aerobic
exercise.
Study Subjects Protocol IGF-I Response
Bang et al., 1990 3 untrained males
3 untrained females
-30 minutes of
continuous cycling
(60% of VO2 max)
-Increased after 10
minutes of
exercise.
Copeland &
Heggie, (in press)
10 physically active
males
-20 minutes of
cycling (60-65%
VO2 max)
-20 minutes of
interval exercise
(80-85% VO2 max)
-Increased with
both exercise
protocols
Dall et al., 2001 8 female rowers
8 male
rowers
-4x5 minutes of
submax rowing
-10 minutes rest
-6 minute max
rowing test
-No change during
exercise
-Decreased post-
exercise.
Elloumi et al.,
2005
11 elite male rugby
players
-1.5 hours match -Increase
Kanaley et al.,
2005
8 untrained males 45 minutes of
continuous cycling
(60% of VO2 max)
-No change
Koistinen et al.,
1996
15 females
10 male
Amateur runners
Marathon -Decrease
Schwarz et al.,
1996
10 untrained males 10 minutes of
continuous cycling
at either a high or
low intensity
-Increased at both
intensities
Suikkari et al.,
1989
11 healthy men 3 hours of
continuous cycling
(45-55% of VO2
max).
-No change
Wilson et al., 1987 28 children -15 minutes of
continuous cycling
(60% above resting
HR)
-No change
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IGFBP-3 Response To Acute Exercise
It is clear from the preceding discussion that acute exercise has an effect on
circulating IGF-I. Since the majority of circulating IGF-I is complexed with and
regulated by IGFBP-3, it is not surprising that exercise may also influence circulating
IGFBP-3. Schwarz et al. (1996) found IGFBP-3 to significantly increase in response to
both 10 minutes of high and low-intensity cycling, however, greater increases were
detected after high-intensity exercise. Copeland and Heggie (in press) also found
increases in IGFBP-3 after 20 minutes of continuous and interval exercise. Similar to
Schwarz et al. (1996), a greater increase was reported after the more intense intermittent
exercise, thus suggesting the possibility of an intensity-dependent response pattern.
The mechanism behind the exercise-induced increase in IGFBP-3 has been
extensively debated. GH is considered to be the primary regulator of IGFBP-3 (Baxter &
Martin, 1986; Blum, Albertsson-Wikland, Roseberg & Ranke, 1993), therefore, it is
reasonable to suggest that an exercise-induced increase in GH would increase IGFBP-3
concentration. However, more recent findings suggest that exercise-induced increase in
IGFBP-3 is GH-independent (Dall et al., 2001; Schwarz et al., 1996). Alternatively, it has
been hypothesized that the exercise-induced increase in IGFBP-3 is regulated by IGF-I
(Kanety, Karasik, Klinger, Silbergeld & Laron, 1993). Koistinen et al. (1996) reported a
positive correlation between IGF-I and IGFBP-3 in response to acute exercise. However,
others have found exercise-induced increases in IGFBP-3 with no increase in IGF-I
(Chadan et al., 1999).
An exercise-induced increase in IGFBP-3 may also be linked to a shift in blood
volume. During exercise, a shift in blood volume from regions with high IGFBP-3
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concentration (i.e. liver) to the peripheral circulation is believed to occur (Koistinen et al.,
1996). Others have suggested that along with a shift in blood volume, an increased influx
of IGFBP-3 into the plasma, decreased IGFBP-3 clearance, and changes in plasma
volume itself may also contribute to changes in circulating IGFBP-3 during exercise (Dill
& Costill, 1974).
In contrast to the reported increase in IGFBP-3 in response to acute exercise,
Koistinen et al. (1996) found IGFBP-3 to remain unchanged immediately following
prolonged exercise. When blood samples were analysed 24-hours post-exercise, IGFBP-3
had significantly decreased compared to pre-race levels. Since previous work has
confirmed the activation of IGFBP-3 proteolysis during physiological stress such as
exercise (Jones & Clemmons, 1995; Rosendal et al., 2002), it is reasonable to suspect that
the enhanced IGFBP-3 proteolysis led to the drop in IGFBP-3. However, since Koistinen
et al., (1996) reported that no significant proteolysis had taken place, it appears that
another unknown mechanism was responsible for the decrease in IGFBP-3.
The inconsistencies among previous findings suggest that multiple factors may
influence the IGFBP-3 response to acute exercise. Recently, Elloumi et al. (2005)
reported that scores from an overtraining questionnaire appeared to be correlated with the
IGFBP-3 response to acute exercise. It was found that more fatigued athletes, as indicated
by higher overtraining scores, presented a decrease in IGFBP-3 concentration after a
rugby match compared to less fatigued athletes who had increased IGFBP-3 after the
match. A decrease in IGFBP-3 is hypothesized to be an important mechanism in
counteracting the catabolic effects of overtraining (Elloumi et al., 2005).
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IGF-Response to Exercise Training
The effect of long-term exercise training on the IGF system is not well
understood. Several studies have indicated that IGF-I levels increase following exercise
training. Increases have been observed following 8 weeks of endurance training
(Poehlman et al., 1994), 6 months of high volume swim training (Koziris et al., 1999),
high intensity cycling twice a day for two weeks (Roelen et al., 1997), and a three-week
cycling race (Chicharro et al., 2001). The mechanism responsible for the increase is
unknown, however, based on the work by Zanconato et al. (1994) it is speculated that an
increase in IGF-I concentration must ultimately be a result of an increase in IGF-I gene
expression.
In contrast to the observed increases, other studies have found IGF-I
concentration to decrease following exercise training. Decreases have been observed
following 5 weeks of endurance and resistance type training in adolescent males (Eliakim
et al., 1998) and females (Eliakim et al., 1996), 11 weeks of physical training in untrained
subjects (Rosendal et al., 2002) and 3 days of intensive gymnastic training (Jahreis et al.,
1991).
Interestingly, other studies have indicated a biphasic IGF-I response to exercise
training. Schmitz, Ahmed and Yee (2002) found that after 15 weeks of resistance training
IGF-I significantly decreased, which was followed by an increase to slightly above
baseline levels in the following 24 weeks of training. Similar results were also found
following two and four weeks of combined endurance and resistance type training
(Eliakim, Nemet, Bar-Sela, Higer & Falk, 2002). It is possible that the initial onset of an
exercise-training program results in hormonal adaptations suggestive of a catabolic state,
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but at a certain point an anabolic rebound occurs (Eliakim et al., 1996). A summary of the
studies that have investigated the IGF-I response to exercise training is provided in Table
2.
Several factors may potentially contribute to these varying results. As discussed
previously, nutritional status has a profound effect on circulating levels of IGF-I. It is
possible that changes in IGF-I reflect changes in nutritional status. It is believed that the
onset of an exercise program may result in an energy-deficient state, in which case IGF-I
will decline (Nemet et al., 2004). However, in contrast, other studies that have indicated a
decrease in IGF-I following exercise training have found no change in body weight or
percent fat, which suggests that an energy deficiency did not occur (Eliakim et al., 1996;
Eliakim et al., 1998).
Training status is another factor that may influence resting IGF-I following
exercise training. Although data is limited, it has been found that IGF-I is affected
differently in trained subjects compared to untrained subjects following 11-weeks of
intense exercise training (Rosendal et al., 2002). IGF-I levels in the trained group
displayed a biphasic response, decreasing from 0 to four weeks and then increasing to
baseline levels from 4 to 11 weeks. In the untrained subjects, IGF-I levels continuously
declined from 0 to 11weeks. From this finding it appears that training status and fitness
level do influence the IGF-I response to exercise training.
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Table 2. Summary of studies examining the IGF-I response to exercise training.
Study Subjects Protocol IGF-I Response
Chicharro et al.,
2001
17 elite cyclists -3 weeks of cycling Increase
Eliakim et al., 1996 44 female high
school students
-5 weeks of aerobic
training
Decrease
Eliakim et al., 1998 44 male high school
students
-5 weeks of aerobic
training
Decrease
Eliakim et al., 2002 12 elite handball
players
-4 weeks of aerobic
and resistance
training
-Decrease the first
2 weeks
-Increase to basal
levels in the
following 2 weeks
Jahreis et al., 1991 16 prepubertal
female gymnasts
-3 days of mixed
athletic training
Decrease
Koziris et al., 1999 19 male
9 female
collegiate swimmers
-6 months of high
volume swim
training
Increase
Maimoun et al.,
2004
7 elite triathletes -32 weeks of
training
Increase
Rosendal et al.,
2002
7 untrained males
12 trained males
-11 weeks of
military training
Decrease in
untrained subjects
-Decrease at 4
weeks, then
increased to pre-
training levels by
11 weeks in trained
subjects
IGFBP-3 Response to Exercise Training
The effects of exercise training on resting IGFBP-3 are poorly documented.
Studies have found intense exercise training to stimulate increases in resting IGFBP-3
(Koziris et al., 1999; Manetta et al., 2003). However, not all studies have observed an
increase in resting IGFBP-3 following exercise training (Chicharro et al., 2001; Maimoun
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et al., 2004; Poehlman et al., 1994; Rosendal et al., 2002). Furthermore, studies have
shown resting IGFBP-3 to decrease following five weeks of exercise training (Eliakim et
al., 1996; Eliakim et al., 1998).  Table 3 provides a summary of the studies that have
investigated resting IGFBP-3 following exercise training.
Similar to IGF-I, numerous factors can influence the resting IGFBP-3 response to
exercise training including nutritional status, age, and the frequency and type of training.
It has been suggested that training status may influence resting IGFBP-3 concentration
following exercise training. Rosendal et al. (2002) found that IGFBP-3 levels decreased
in untrained subjects from baseline to week 4 and then returned to baseline levels in the
following 4 weeks, where as no change was observed with in well trained individuals.
The mechanism responsible for the decrease in the untrained subjects is believed to be a
result of increase IGFBP-3 proteolysis, which has been supported by others (Jones &
Clemmons, 1995; Schwarz et al., 1996). Rosendal et al. (2002) reported that the
physiological stress needed to stimulate proteolytic activity is potentially correlated with
the initial training status of the individual. It is believed that the 11 weeks of training was
sufficient to stimulate changes in IGFBP-3 in the untrained subjects, whereas higher
intensities would be needed for the same response in the trained group (Rosendal et al.,
2002).
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Table 3. Summary of studies examining the IGFBP-3 response to exercise training.
RELATIONSHIP BETWEEN IGF-I, IGFBP-3 AND TRAINING STATUS
Establishing optimal training volumes and monitoring athletes’ training status are
constant challenges for trainers, coaches and athletes themselves. Insufficient training
volumes may impair results, whereas training too much can potentially lead to
overtraining. Overtraining syndrome (OTS) is a severe yet common condition in many
elite athletes’ careers. According to Morgan et al. (1987), 65% of all endurance athletes
have reported overtraining symptoms at some time in their competitive career. OTS is a
complex neuroendocrine disorder that is characterized by poor sport performance despite
Study Subjects Protocol IGFBP-3
Response
Chicharro et al.,
2001
17 elite cyclists -3 weeks of cycling  No change
Eliakim et al.,
1996
44 male high school
students
-5 weeks of aerobic
training
Decrease
Eliakim et al.,
1998
44 female high school
students
-5 weeks of aerobic
training
Decrease
Koziris et al.,
1999
19 male swimmers
9 female swimmers
-6 months of high
volume swim training
Increase
Maimoun et al.,
2004
7 elite triathletes -8 months of intense
training
No change
Manetta et al.,
2003
8 male cyclist
8 sedentary males
-4 month of cycling
(17hours per week)
Increase
Poehlman et al.,
1994
10 older males
8 older females
-2 months of cycling
(3 days per week)
No change
Rosendal et al.,
2002
7 untrained males
12 trained males
-11 weeks of military
training
No change
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appropriate rest, persistent muscle soreness, inability to maintain training loads, mood
disturbances, reduced catecholamine secretion, frequent illness and sleep disturbances
(Hug, Mullis, Vogt, Ventura & Hoppeler, 2003).
Currently there are no consistent diagnostic parameters for detecting OTS. The
most frequently used indicator for OTS is a decrease in athletic performance (Armstrong
& VanHeest, 2002). The other commonly used indicator is a psychological measure, such
as profile of mood state (POMS) questionnaire (McKenzie, 1999). As an individual
becomes overtrained, they tend to score higher on the POMS, which indicates a negative
mood state (Reitjens et al., 2005).
Although data is limited, IGF-I and IGFBP-3 may also have utility in monitoring
training status and detecting OTS because of their relationships with various
measurements of fitness. Cappola et al. (2001) found IGF-I to be significantly correlated
with knee extensor strength in elderly women, while other studies have found IGF-I to be
significantly related to VO2 max in both elderly and young men (Kelley et al., 1999;
Poehlman & Copeland 1990). Manetta et al. (2003) reported a correlation between
IGFBP-3 and VO2 max following four months of training in previously trained cyclists.
However, it is difficult to draw conclusions about the relationship between training status
and IGF-I and IGFBP-3 because of the cross-sectional design of these previous studies.
Recently, Elloumi et al. (2005) found that the IGFBP-3 response to acute exercise
was inversely related to scores on a standardized overtraining questionnaire. Thus, as
symptoms of overtraining increased, IGFBP-3 levels decreased. Previous studies have
evaluated resting IGFBP-3 following exercise training (Koziris et al., 1999), however,
there has been little work done to explore the relationships between IGFBP-3 and training
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status in younger individuals engaging in long-term training. It would be beneficial to
understand the effects of long-term training on IGFBP-3 levels as it may provide an
effective tool for monitoring training status and the detecting the early signs of
overtraining.
SUMMARY AND RATIONALE OF THE STUDY
Circulating levels of IGF-I and IGFBP-3 are regulated by many factors including
age, nutritional status and GH concentration. Accumulating evidence now suggests that
exercise is a major regulator of the IGF system. Several studies have shown that acute
bouts of intense aerobic exercise results in transient increases in IGF-I and IGFBP-3
(Bang et al., 1990; Dall et al., 2001; Elloumi et al., 2005). However, the effects of
exercise training on resting IGF-I and IGFBP-3 are less definitive. Studies have indicated
that exercise training can induce an increase in resting IGF-I and IGFBP-3 (Chicharro et
al., 2001; Koziris et al., 1999), while others have reported decreases (Eliakim et al., 1998;
Eliakim et al., 1996; Jahreis et al., 1991). Due to these inconsistent results, it is thought
that a training threshold may exist that describes the physiological stress applied during
exercise training. Although many factors are thought to influence an individual’s
threshold profile, fitness and level of training status may mediate the effect of exercise on
IGF-I. The relationship between measures of training status and resting IGF-I and
IGFBP-3 levels during long-term training remains poorly documented.
The primary purpose of this study was to assess the effects of exercise training on
resting levels of IGF-I and IGFBP-3. Due to start date of the competitive season and the
volume of training, varsity swimmers were chosen for this study. Given the number of
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elite endurance sports that employ a long training season, it would be relevant to
understand whether training status is related to IGF-I and IGFBP-3 concentrations.
Therefore, the second purpose of this study was to determine if changes in resting IGF-I
and IGFBP-3 were associated aerobic power, athletic performance, or symptoms of
overtraining. An understanding of how training status, and potentially overtraining affects
IGF-I and IGFBP-3 would assist athletic trainers, coaches and athletes in identifying
optimal training volumes. Understanding this relationship could also be beneficial for
elite athletes as it may allow early detection of OTS so that appropriate preventive
measures can be taken.
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CHAPTER 3
METHODOLOGY
SUBJECT RECRUITMENT AND SCREENING
12 Elite swimmers (5 males and 7 females) from the University of Lethbridge
swim team between the ages of 18 and 25 were recruited for the study. All participation
was voluntary; no material incentive was provided and subjects were free to withdraw
from the study at any time. All subjects were non-smokers and free from any medications
that may influence growth factor concentration or athletic performance. All female
subjects recruited for the study reported that they were using an oral contraceptive. All
subjects read and understood the experimental procedures and the potential risks and
benefits, and written informed consent was obtained.
To ensure participant safety, all subjects completed a Physical Activity Readiness
Questionnaire (PAR-Q) and a medical health questionnaire (Appendix C). The medical
health questionnaire was administered to provide information about any medications that
the subject was taking and relevant medical history. Prior to testing, resting heart rate and
blood pressure were measured. As required by the Canadian Society of Exercise
Physiology (CSEP) resting heart rate and resting blood pressure was below 100 beats per
minute (bpm) and 145/95 mmHg respectively.
EXPERIMENTAL PROCEDURES
The study consisted of three testing phases, each using the same protocols and
measurements. Initial testing took place in mid-September, which was prior to the onset
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of intensive training (week 0). The second testing phase took place eight weeks after the
initial testing during a one-week tapering phase (week 8). The third testing phase took
place 16-weeks after initial testing during a one-week tapering phase (week 16). Figure 3
represents a schematic diagram of the experimental procedures utilized during the study.
During each phase of testing, subjects were required to attend two sessions on
consecutive days at the University of Lethbridge Exercise Physiology lab. The first
session involved completing a standardized overtraining questionnaire proposed by the
French Society of Sports Medicine (SFMS), and the collection of a resting blood sample
in order to establish serum total IGF-I and IGFBP-3 concentrations. During the second
session, fitness measurements were obtained, which included anthropometric measures
(skinfold measurements, height, weight), maximal aerobic fitness (VO2 max), resting and
maximal blood lactate, and maximal heart rate. In addition to the data collected during
the three sessions, results of a time trial for each subject in their dominant event were also
obtained at each phase. The time trials were used as a measure of each subject’s athletic
performance throughout the study period. Subjects were also required to document their
nutritional intake three days prior to the first session of each phase so that nutritional
status could be monitored across each testing phase.
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Figure 3. Schematic diagram of the experimental procedures of the study
SFMS Scores
Prior to collecting resting blood samples, a standardized overtraining
questionnaire developed by the French Society of Sports Medicine (SFMS) (Appendix B)
was completed by each subject. Results from the questionnaire provided a SFMS score
for all subjects across all three testing phases. The SFMS questionnaire was chosen for
this study because of its reliability and sensitivity to changes in training status (Brun,
2003). The questionnaire was also chosen for this study because it is easy to administer
and clear for participants to understand (Brun, 2003). The questionnaire consists of 54
“Yes or No” questions. The score is calculated summing the total number of yes answers.
Week 0 Week 8 Week 16
8 weeks of training 8 weeks of training
1-week
tapering
1-week
tapering
Session 1
-3-day food record
-Overtraining
questionnaire
-Resting blood
sample
Session 2
-Anthropometrics
VO2 max
-Rest/max lactate
-Max Hr
Time Trial
Session 1
-3-day food record
-Overtraining
questionnaire
-Resting blood
sample
Session 2
-Anthropometrics
VO2 max
-Rest/max lactate
-Max Hr
Time Trial
Session 1
-3-day food record
-Overtraining
questionnaire
-Resting blood
sample
Session 2
-Anthropometrics
VO2 max
-Rest/max lactate
-Max Hr
Time Trial
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A score equal to or greater than 20 is suggestive of overtraining (Brun, 2003; Maso, Lac
& Brun, 2005).
Blood Sampling
To establish resting levels of total IGF-I and IGFBP-3, blood samples were taken
from each subject. A week before sampling, subjects were given strict pre-testing
guidelines, which included a 12 hour fast prior to sampling and to refrain from alcohol or
caffeine intake for 24 hours prior to sampling. Also, subjects were asked to refrain from
strenuous physical activity for 24 hours prior to sampling. All samples were taken in a
climate-controlled environment. The sampling procedures were performed between 6:30
and 8:30 am at each phase to control for any diurnal variations in growth factor levels. To
assess daily variation in resting IGF-I and IGFBP-3 concentration, 75 percent of the
subjects had a second sample of blood drawn the next day utilizing the same procedures.
Blood samples were drawn under sterile conditions by an individual trained in
phlebotomy procedures.
Approximately seven millimeters of venous blood was drawn into red top
vacutainer tubes from an antecubital arm vein. The blood was then allowed to clot at
room temperature for 15 minutes. The clotted samples were centrifuged at 3000 rpms, at
4oC for 15 minutes. The resulting serum was extracted and stored at –80 C until it was
assayed.
Anthropometric Data
The anthropometric data that were collected included height (nearest 0.5 cm),
weight (nearest 0.1 kg), body mass index (BMI)(kg/m2), and percent fat, which was
calculated via skinfold thickness. Skinfolds were taken according to the Jackson Pollock
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7-site method (Jackson & Pollock, 1985). All skinfold measurements were performed by
the principle investigator using a Harpenden skinfold caliper.
Aerobic Power
For the assessment of maximal oxygen consumptions (VO2 max), subjects
performed a maximal cycle ergometer test according to the Astrand graded exercise cycle
test protocol (Astrand, 1965) (Fig. 4). All VO2 max tests were performed on the Monark
Ergomed 818E cycle ergometer (Monark, Varberg, Sweden). Oxygen consumption was
measured using the Vista Mini CPX open-circuit spirometry system (VacuMed, Ventura,
CA). Expiratory gases were analysised in 15-second averages and displayed using
TurboFit 5.4 software (VacuMed, Ventura, CA). Prior to each phase of testing the cycle
ergometer was calibrated for resistance, while the gas analyzers were calibrated to three
standards; nitrogen, room air and a known calibration gas.
Prior to the onset of testing, subjects were introduced to the cycle ergometer and
safety procedures. Subjects were also familiarized with the Borg Rating of Perceived
Exertion Scale (Borg, 1982). Once the subject felt comfortable, a 5-minute warm-up
followed by passive stretching was performed. Subjects were then attached to the gas
collection apparatus and two minutes of resting values were obtained to ensure the
system was working properly.
Subjects were instructed to maintain a pedal rate of 60 RPM throughout the
entirety of the test. The male subjects started at a resistance of 1.5 kg and the female
subjects started at 1.0 kg.  Every two minutes the resistance was increased by 0.5 kg until
exhaustion. Immediately following test termination the subject started a 5-minute active
cool down.
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Figure 4. VO2 max test protocols used for both males and females subjects.
Lactate
Following pre-screening, subjects were instructed to sit in a quiet and relaxed
state for five minutes. A finger prick was then performed to collect a capillary blood
sample. The sample was analyzed using the Lactate Pro portable lactate analyzer (Arkray
Factor Inc., Shiga, Japan) to determine the pre-exercise blood lactate level. This same
procedure was performed five minutes after the max VO2 test in order to establish a
maximal blood lactate level.
Heart Rate
Both pre-exercise and maximal heart rates were obtained using a Polar telemetric
heart rate monitor (Polar Electro, Kempele, Finland). The subject sat quietly for five
minutes before a resting heart rate was collected. Heart rate was recorded continuously
during the maximal treadmill test and following the test the data were downloaded and
the maximum heart rate attained during the test was identified.
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Nutritional Assessment
To evaluate nutrient intake, all subjects completed a 3-day food record prior to the
first session at each phase of testing. Detailed information about the procedure was
explained and all subjects received three blank recording sheets (Appendix B). Subjects
were instructed not to change their regular eating habits during the recording. Each
subject’s diet was analyzed for total caloric intake and protein consumption using
Nutritionist Pro v.2.5.1 software (First Databank Inc., TX).
Athletic Performance
Once during each phase of testing a time trial from each subjects dominant event
was collected. The times at each phase were obtained during a competition, which took
place no longer than one week following that testing phase.  The time trials represented a
measurement of each subject’s sports-specific athletic performance.
BIOCHEMICAL ANALYSES
Serum concentration of total IGF-I and IGFBP-3 were estimated using an
Enzyme-Linked Immunosorbent Assay (ELISA) (Diagnostic Systems Laboratories Inc.,
TX.). All samples were analysed in duplicate and all samples from each subject were
analysed in the same assay to minimize the effects of inter-assay variation. High and low
controls were included in each assay to evaluate inter-assay variation. Table 4 reports the
acceptable and average intra-assay coefficient of variation for IGF-I and IGFBP-3. Also,
reported are the inter-assay coefficient of variation for both high and low controls, and
the sensitivity of each assay procedure. Procedures for both IGF-I and IGFBP-3 assays
are available in Appendix E.
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Table 4. Intra- and inter-assay coefficient of variations and sensitivity of assays.
Acceptable
Intra-assay
Coefficient
of Variation
Average
Intra-assay
Coefficient
of Variation
Average Inter-assay
Coefficient of Variation
Low               High
Sensitivity of
Assay
IGF-I 10% 4.2% 9.5% 4.8% 0.01 ng/mL
IGFBP-3
10%
5.3% 10.3% 3.1% 0.04 ng/mL
STATISTICAL ANALYSIS
Descriptive data are expressed as means and standard deviations (SD). Repeated
measures analysis of variance (ANOVA) was used to examine differences in variables
measured at week 0, 8 and 16. If main effects were established, pairwise comparisons
were conducted and adjusted for multiple comparisons (Bonferroni). Pearson product
moment correlations were performed to analyze relationships between biological,
physical and psychological variables. Data analysis was performed using SPSS v14
software.  The significance threshold was set at p<0.05.
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CHAPTER 4
RESULTS
SUBJECT CHARACTERISTICS
All subjects attended a minimum of 85 percent of the scheduled team practices
throughout the study period. Average weekly training distances (m) for each month are
shown in Table 5. On average, subjects have been swimming competitively for nine
years. Subject characteristics including gender, age and years of varsity training are
presented in Table 6.
Table 5.  Team training volumes from the beginning to the end of the study period.
Note: Values are rounded to the nearest 100 m. Subjects did not train for one week in
December, which was not included in the average.
Table 6.  Participant gender, age and years of training experience
Subject Gender Age (Years)
Years of Varsity
Training
1 M 24 3
2 M 22 5
3 M 20 2
4 M 20 2
5 M 19 3
6 F 20 3
7 F 18 1
8 F 21 3
9 F 20 1
10 F 19 2
11 F 18 1
12 F 20 4
Mean
SD±
20.1
±1.68
2.5
±1.24
Average Weekly Training Distance (m)
September October November December January
14 400 19 900 25 000 22 300 21 000
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NUTRITIONAL STATUS
Figures 5 and 6 illustrate the individual and mean data for the average relative
calorie and protein intake for the three days prior to testing. There was no significant
difference in calorie or protein intake across the three testing phases.
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 Figure 5.  Individual and mean data for the average relative daily calorie intake for
the three days prior to each testing period (kcal/kg/day).
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Figure 6. Individual and mean data for the average relative daily protein intake for
the three days prior to each testing period (g/kg/day).
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FITNESS AND ATHLETIC PERFORMANCE
Table 7 presents individual anthropometric data measured at each testing phase of
the study. Body fat percentage was significantly decreased at week 8 and week 16 when
compared to week 0 (p<0.05). Changes were apparent in all other variables measured,
however, statistical significance was not achieved.
Table 7.  Individual anthropometric data.
Weight (kg) BMI (kg/m2) Body fat (%)
Subject Gender Week
0
Week
8
Week
16
Week
0
Week
8
Week
16
Week
0
Week
8
Week
16
1 M 76.5 75.5 76.6 23.35 23.05 23.38 11.60 9.46 11.36
2 M 107.0 107.1 107.7 34.35 34.38 34.57 21.10 18.62 19.12
3 M 68.2 67.4 67.6 19.50 19.27 19.33 8.32 6.43 7.64
4 M 69.6 72.5 72.8 22.85 23.81 23.91 9.12 10.37 9.736
5 M 69.7 73.2 72.2 20.70 21.74 21.44 10.73 12.42 11.57
6 F 51.7 51.1 51.4 18.32 18.11 18.21 11.00 9.30 8.429
7 F 74.3 70.2 72 26.17 24.73 25.35 20.09 16.57 15.85
8 F 58.2 57.7 56.6 21.00 20.81 20.4 13.08 10.02 9.84
9 F 78.0 75.2 73.8 24.34 23.47 23.03 23.93 20.72 19.30
10 F 64.7 62.1 62.8 21.37 20.51 20.74 20.78 15.87 18.34
11 F 62.7 64.5 63.9 22.48 23.13 22.91 17.57 17.92 15.64
12 F 76.0 75.3 76.6 26.45 26.21 26.66 23.48 20.44 21.74
Mean 71.38 70.98 71.17 23.41 23.27 23.33 15.90 14.01* 14.05*
SD± 13.70 13.73 13.96 4.23 4.19 4.30 5.83 4.91 4.85
*Significantly different from week 0, p<0.05
Table 8 presents individual maximal exercise data measured at each testing phase
of the study. No significant differences were found in any of the maximal exercise
variables. Figure 7 compares individual and mean athletic performance at all three testing
phases. After eight weeks of training (week 0 to week 8), all subjects increased their
athletic performance on average 3.24% (ranging from 0.51 to 11.36%). In the following
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eight weeks of training (week 8 to week 16), eight subjects showed an improvement in
athletic performance, while four subjects showed a decrease in athletic performance.
Table 8.  Individual maximal exercise data
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Figure 7.  Individual data for the relative change in athletic performance across all
testing phases.
V02 max (ml/kg/min) Max HR Max lactate
Subject Week
0
Week
8
Week
16
Week
0
Week
8
Week
16
Week
0
Week
8
Week
16
1 51.4 47.8 48.1 174 184 184 12.6 11.9 10.0
2 40.4 40 39.1 190 194 189 8.3 9.6 10.4
3 59.0 62.3 58.2 186 181 180 7.8 7.0 8.2
4 65.3 63.6 64.8 194 184 193 8.4 10 12.2
5 46.4 43.3 44.7 197 194 187 14.6 14.7 12.7
6 48.2 48 50 202 198 197 11.9 9.0 8.6
7 39.1 38.3 40.9 198 195 195 8.1 6.9 8.2
8 51.6 52.4 54 182 178 181 11.3 9.3 9.0
9 41.4 40.5 42 172 174 173 8.4 9.2 9.9
10 46.4 53.8 51.9 192 194 198 7.8 11.3 12.8
11 45.5 45 46.8 194 190 191 12.2 9.0 15.2
12 36.6 38.7 34.8 171 171 162 10.8 9.6 7.4
Mean 47.6 47.8 47.9 187.7 186.4 185.8 10.2 9.8 10.4
SD± 8.34 8.70 8.49 10.65 9.03 10.62 2.33 2.11 2.37
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Individual and mean SFMS scores at the three testing phases of the study are
illustrated in Figure 8. On average, SFMS scores were elevated by 81% at week 8 and
66% at week 16 when compared week 0, which indicated greater symptoms of
overtraining following 8 and 16 weeks of training. The observed changes in SFMS scores
did not reach statistical significance.
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Figure 8.  Individual and mean data for SFMS scores at all three testing phases of
the study.
RESTING GROWTH FACTOR AND BINDING PROTEIN LEVELS
Figures 9-11 represent the average concentration of IGF-I, IGFBP-3 and the IGF-
I/IGFBP-3 ratio at each of the testing phases. There were no significant differences in
IGF-I, IGFBP-3 or IGF-I/IGFBP-3 ratio across testing sessions. However, when the IGF-
I data were normalized to baseline values and expressed as percent change, there was a
significant difference in results from 0 to 8 weeks versus 8 to 16 weeks (Figure 12). To
assess the daily variability in IGF-I and IGFBP-3 levels, two samples were collected on
consecutive days for 75% of the sampling sessions. The intraclass correlation between
daily IGF-I samples was 0.924 and between IGFBP-3 was 0.915, which indicates little
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daily variation. For these samples an average of the two daily concentrations were used in
the analysis and the remaining 25% of values are based on a sample from one day only.
Individual results for IGF-I, IGFBP-3 and IGF-I/IGFBP-3 ratio can be seen in Appendix
C.
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Figure 9. Mean IGF-I concentration at the three testing phases of the study (Mean ±
SE).
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Figure 10. Mean IGFBP-3 concentration at the three testing phases of the study
(Mean ± SE).
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 Figure 11.  Mean IGF-I/IGFBP-3 ratio at the three testing phases of the study
(Mean ± SE).
Figures 12 and 13 present the average percent change in IGF-I and IGFBP-3
between testing sessions, respectively. Results from a paired t-test revealed that the
change in IGF-I concentration measured between 0 to 8 weeks (11.9%) was significantly
different when compared to the change measured between 8 to 16 weeks (-4.9%)
(p<0.01). An average 6% increase in IGFBP-3 was observed between 0 and 8 weeks,
however, statistical significance was not achieved. Individual results for relative change
and absolute change in IGF-I and IGFBP-3 are available in Appendix D.
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Figure 12. Average relative change in IGF-I between all phases of the study (Mean ±
SE).
* Significant difference in relative change in IGF-I level between 0 to 8 weeks compared to 8 to 16
weeks p<0.05.
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 Figure 13. Average relative change in IGFBP-3 between all phases of the study
(Mean ± SE).
Resting IGF-I and IGFBP-3 levels in both male and female subjects at all testing
phases of the study are illustrated in Figures 14 and 15, respectively. Although the
purpose of the present study was not to investigate the gender differences in IGF-I and
IGFBP-3 across training, an analysis between genders was necessary to justify including
data from both genders into one group. Although IGFBP-3 levels were significantly
greater in the female group (p<0.05), these figures illustrate that the changes in IGF-I and
IGFBP-3 during training were similar in both genders.
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Figure 14. IGF-I concentrations in both male and female subjects at all three testing
phases (Mean ± SE).
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Figure 15. IGFBP-3 concentrations in both male and female subjects across all three
testing phases (Mean ± SE).
* Significantly greater IGFBP-3 concentration in female compared to male subjects at all time points,
p>0.05.
There was a significant positive correlation between IGFBP-3 and SFMS scores
at week 0, however, this relationship did not persist after 8 or 16 weeks of training
(Figure 16). As seen in Figure 17, there was no correlation between IGF-I and SFMS at
any of the testing phases. When IGF-I and IGFBP-3 concentrations were compared
between subjects that had SFMS scores greater than 20 and SFMS score less than 20,
there were no significant differences in IGF-I or IGFBP-3 concentration across the testing
phases for either group. There was no significant relationship between other measures of
training status and circulating concentrations of either IGF-I of IGFBP-3.
* **
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Figure 16. The relationship between IGFBP-3 and SFMS scores at pretesting, after
8 and 16 weeks of training.
*Significant correlation (p<0.05)
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Figure 17. The relationship between IGF-I and SFMS scores at pretesting, after
8 weeks and 16 weeks of training.
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CHAPTER 5
DISCUSSION
SUMMARY OF FINDINGS
The aim of this study was two-fold. The first goal was to evaluate the effects of
long-term swim training on resting levels of IGF-I and IGFBP-3, and the second goal was
to determine if changes in IGF-I and IGFBP-3 were related to changes in training status.
It was hypothesized that IGF-I and IGFBP-3 would increase with increased fitness and
athletic performance.  In the present study, the relative change in IGF-I from week 0 to
week 8 (11.93%) was significantly greater than the relative change from week 8 to week
16 (-4.99%). There were no statistically significant changes in absolute or relative
IGFBP-3, VO2 max, athletic performance, or SFMS scores across the 16-week training
period. Resting levels of IGFBP-3 were significantly positively correlated with SFMS
scores at the start of the season, however, this relationship did not persist following 8 or
16 weeks of training. There was no correlation between any of the other measures of
training status and IGF-I or IGFBP-3.
FITNESS MEASURES
The study participants were varsity athletes who had been swimming
competitively for an average of 9 years. Although measures of fitness did not differ
across the testing phases, percent body fat was significantly decreased at week 8 and 16
when compared to pretesting. A decrease in relative body fat is expected with long-term
training and this result is consistent with previous swim-training studies (Koziris et al.,
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1999). It was expected that VO2 max would increase with training, however,
improvements in VO2 max were not detected in the present study. This may in part be
due to the subject’s initial aerobic fitness levels. The average VO2 max was 47.61
ml/kg/min and is rated as “Excellent” among the normal population (Heyward, 1998).
Although a VO2 max of 47.61 ml/kg/min may appear low for elite endurance athletes,
VO2 max tests performed on a cycle ergometer as in the present study can produce VO2
max values that are 5-10% lower than tests performed on treadmill protocols (McArdle,
Katch & Katch, 2007) and 15% lower than those performed on a swimming specific
protocol (Vorontsov, Solomatin & Sidorov 1985). This finding is consistent with the VO2
max of elite swimmers between the ages of 18-22 years, which was reported by
Vorontsov et al. (1985). The initial VO2 max in the present study may be high because
eight of the twelve reported to have trained a minimum of three times per week during
the off-season. Since initial VO2 max was relatively high, the magnitude of any
improvements would be small (McArdle et al., 2007). Other studies have also reported no
significant changes in VO2 max in trained athletes after additional long-term training
(Eliakim et al., 1996; Maimoun et al., 2004; Rosendal et al., 2002; Rietjens et al., 2005).
SFMS scores were increased 82% after 8 weeks and 66% after 16 weeks of
training. This finding suggests that on average, symptoms of overtraining were elevated
at week 8 and week 16. However, other possible physiological symptoms of overtraining
such as a decrease in maximum heart rate, a decrease in maximal lactate or a decrease in
athletic performance were not observed across the testing phases. The overtraining
questionnaire is a subjective evaluation and therefore SFMS scores may be affected by
factors other than training status such as illness or stress. It was noted that six of the
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twelve participants at week 8 and two participants at week 16 reported having flu-like
symptoms, which may have influenced their SFMS scores. It is also reported that scores
from the questionnaire may increase with increased training, however, scores higher than
20 are suggestive of overtraining or a situation at risk for it (Brun, 2003).
RESTING IGF-I AND IGFBP-3 LEVELS
Mean resting levels of IGF-I and IGFBP-3 were within reference levels provided
by Diagnostic Systems Laboratories (Webster, TX)(Appendix D). Individual data
indicated that only one subject at one testing phase had IGF-I levels outside the reference
range. It is noted that this subject did have the highest IGF-I levels in all three testing
phases of the study, and this subject was also the youngest subject in the study. It is well
established that IGF-I levels are higher in younger subjects (Hall et al., 1980).
Individual data also indicated that three subjects had IGFBP-3 levels that were
higher than expected at all three testing phases. All three of these values came from
female subjects of varying age (18-21yrs), and female subjects typically express higher
concentration of IGFBP-3 compared to male subjects (Lofqvist et al., 2004). Based on the
finding from Lukanova et al. (2001), it is believed that neither the use of oral
contraceptives or menstrual cycle phase had a significant influence on the IGFBP-3
levels.
TRAINING EFFECTS ON RESTING IGF-I
Several studies have indicated that physically fit subjects have higher circulating
levels of IGF-I compared to their unfit counterparts (Kelley et al., 1990; Poehlman &
Copeland, 1990). Therefore, increased training and fitness levels may result in increased
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circulating levels of resting IGF-l. In the present study there were no significant
differences in resting IGF-I concentrations after 8 or 16 weeks of exercise training.
However, when the data were normalized to baseline values and expressed as percent
change, there was a significant difference in results from 0 to 8 weeks versus 8 to 16
weeks.
Our findings do not support the previous work by Koziris et al. (1999), who found
circulating levels of IGF-I to increase 70-80% with long-term swim training. The
difference in results may be explained by the differences in the training protocols. The
average weekly training distances for each month is significantly greater in the present
study compared to Koziris et al. (1999) and it is known that exercise volume is an
important determinant of hormonal response (Tremblay, Chu & Mureika, 1995).
Although the volume was reported to be significantly lower in Koziris et al. (1999) it is
possible that the intensity of training was greater than in the present study, or that
additional dry land training, such as resistance training was greater in the Koziris study,
which could have influenced the hormonal response.
It is also possible that the differences are not due to training variables, but rather
due to the type of blood sample collected (i.e. resting vs. acute exercise sample). In the
present study all subjects were asked to refrain from physical activity 24 hours prior to
blood sample collection in an attempt to eliminate the influence of acute exercise on
resting IGF-I levels. This is important because acute exercise typically leads to transient
increases in IGF-I (Bang et al., 1990; Copeland & Heggie, in press; Schwarz et al., 1996).
It is possible that the samples Koziris and colleagues collected were influenced by
previous exercise.
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In contrast to the present results, Eliakim et al. (2002), found circulating levels of
resting IGF-I to decrease after two weeks of exercise training, followed by an increase to
baseline levels in the following two weeks. It is believed that the sudden onset of an
exercise-training program may first lead to a hormonal adaptation suggestive of a
catabolic state, but at some point, an anabolic rebound occurs (Eliakim et al., 2002).
Similar findings were reported by Rosendal et al. (2002) who also found a decrease in
IGF-I after four weeks of training, followed by an increase to baseline levels in the
proceeding seven weeks of training. These findings would suggest that any training
induced changes in IGF-I may be transient. In the present study, blood samples were
collected at eight-week intervals, therefore, it is possible that changes in IGF-I may have
occurred in the early stages of training and not detected. The biological significance of a
transient increase in IGF-I is unknown.
Manetta et al. (2003) reported no change in IGF-I after 4 months of intense cycle
training. Similar to the present study, Manetta et al. (2003) eliminated the influence of
acute exercise on resting levels of IGF-I by having subjects refrain from physical activity
for three days prior to blood sampling. This finding supports the idea that IGF-I may
often be influenced by prior exercise.
The nutritional status of the subjects in the present study remained relatively
consistent across all three testing phases. On average, calorie intake was 33.74
kcal/kg/day and protein intake was 1.30 g/kg/day across all testing phases. Both calorie
and protein intake in the present study were previously found to be adequate in
maintaining normal level of IGF-I (Smith et al., 1987). Nutritional status is important
because energy deficiency in humans is associated with a decline in serum IGF-I
63
(Clemmons et al., 1981; Nemet et al., 2004; Ross, 2000; Smith, Underwood &
Clemmons, 1995), where as overfeeding is associated with an increase in IGF-I (Forbes
et al., 1989). In studies that have reported changes in IGF-I, but did not evaluate
nutritional status, it is possible that change in IGF-I were influenced by changes in
nutritional status.
I hypothesized that resting levels of IGF-I would increase with increasing fitness
and athletic performance. There were no significant changes in VO2 max or athletic
performance across the testing phases. This suggests either the participants started the
season with high levels of fitness, or the training program was not sufficient to stimulate
changes in VO2 max or athletic performance. Anecdotal evidence from the athletes and
the coaching staff indicated that both the training and competitive season was considered
sub-par. It was reported that numerous injuries and illnesses significantly affected the
teams’ results. It cannot be ruled out that if increases in fitness and athletic performance
had occurred, changes in serum IGF-I may also have been observed.
TRAINING EFFECTS ON RESTING IGFBP-3
Since IGFBP-3 plays an important role in the regulation of IGF-I bioavailability,
it was hypothesized that not only would IGF-I increase with increased fitness and athletic
performance, but resting IGFBP-3 would also increase, which would regulate IGF-I
action. However, IGFBP-3 remained consistent across all three testing phases. This is in
agreement with Rosendal et al. (2002) and Maimoun et al. (2004) who found no change
in resting levels of IGFBP-3 in previously trained subjects following extended physical
training. These results would suggest exercise training does not affect resting levels of
IGFBP-3.
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In contrast, Rosendal et al. (2002) found IGFBP-3 to significantly decrease
following training in previously untrained subjects. It was confirmed that the decrease in
IGFBP-3 was the result of increased IGFBP-3 proteolysis and was suggested that the
relative stress of training must exceed a certain threshold in order for proteolysis and a
subsequent decline in IGFBP-3 to occur. It is possible that the athletes in the present
study did not exceed the relative stress needed to stimulate IGFBP-3 proteolysis and with
a greater training load (intensity X duration), a change in IGFBP-3 may have been
observed.
Exercise induced changes in IGFBP-3 are important because changes in IGFBP-3
affect the IGF-I/IGFBP-3 ratio, which provides an index of IGF-I bioavailability. Greater
IGF-I bioavailabity means more anabolic effects of IGF-I can be expressed. In the present
study, the IGF-I/IGFBP-3 ratio was unchanged following 8 and 16 weeks of training,
suggesting that the bioavailability of IGF-I was also unchanged. This finding is in
agreement with Koziris et al. (1999) who also found no significant difference in IGF-
I/IGFBP-3 ratio with training.
Based on the finding from previous studies, it appears the relative stress produced
by the training in the present study was not sufficient to stimulate changes in resting
IGFBP-3. This could be due to the training program and the initial fitness levels of the
participants. It cannot be ruled out that the participants’ adherence to the training program
and the intensity at which they trained were low and also influenced this result.
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RESTING IGF-I AND IGFBP-3 AND MEASURES OF TRAINING STATUS
Changes in training status may be associated with adaptations in the IGF-I system
(Eliakim et al., 2002; Elloumi et al., 2005; Manetta et al., 2003; Poehlman & Copeland,
1990). It was therefore expected that increases in resting IGF-I or IGFBP-3 would be
significantly correlated with changes in measures of training status including VO2 max,
athletic performance and SFMS scores.
There was no correlation between IGF-I or IGFBP-3 and VO2 max in the present
study. This finding supports some previous studies, which also found no significant
relationship (Eliakim et al., 1996). Poehlman & Copeland, (1990) reported a significant
relationship between changes in IGF-I and VO2 max in elderly, previously untrained
subjects following exercise training. Manetta et al. (2003) also found a significant
relationship between IGFBP-3 and predicted VO2 max in previously trained subjects
following four months of intense training. However, in the present study, VO2 max did
not change across the 16 weeks, therefore this study cannot confirm if IGF-I or IGFBP-3
is a sensitive marker of changes in VO2 max.
IGFBP-3 levels have been suggested as a possible marker for the catabolic effects
of overtraining. Elloumi et al. (2005) found that changes in IGFBP-3 following acute
exercise are negatively correlated with scores on an overtraining questionnaire. Elloumi
et al. (2005) suggested that IGFBP-3 levels decline as athletes become fatigued and that a
decrease in IGFBP-3 compensates for the catabolic state of overtraining by increased
IGF-I bioavailability. Despite an increase in SFMS scores, this study did not confirm a
relationship between change in SFMS scores and change in resting IGFBP-3. A positive
correlation between resting levels of IGFBP-3 and SFMS was noted at the week 0 in the
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present study. This indicates that subjects with more symptoms of fatigue had higher
levels of IGFBP-3, which is the opposite of what was expected. The significance of this
finding is not known and it should be noted this relationship did not persist following 8 or
16 weeks of training. Due to the high variability in physiological responses of these
athletes to training and school related stress, perhaps more subjects are needed to detect
the relationship. It is important to note that Elloumi et al. (2005) reported a negative
relationship between the change in IGFBP-3 following acute exercise and scores from the
overtraining questionnaire. It is also noted that only one subject in the present study had a
SFMS score that was suggestive of overtraining at week 0, while Elloumi reported three
subjects with scores that were suggestive of overtraining. Together these findings indicate
that changes in IGFBP-3 level following acute exercise may be a possible marker of
overtraining, however, resting levels of IGFBP-3 appear to be a poor indicator of
overtraining symptoms.
CONCLUSIONS AND RECOMMENDATIONS FOR FUTURE WORK
This study cannot confirm the hypothesis that resting levels of IGF-I and IGFBP-
3 increase with increased fitness and athletic performance. Several factors may have
influenced our results including subject’s initial fitness levels. Highly trained athletes
show little improvements in fitness levels and have blunted a hormone response
compared to untrained subjects. It is also possible that the participants in this study did
not train with sufficient intensity to stimulate changes in the IGF-I system. It cannot be
ruled out that if changes in fitness would have been observed in the present study,
changes in the IGF system may have also been observed.
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Although the absolute change in IGF-I did not change across the testing phases,
the relative change in IGF-I was significantly different from 0 to 8 weeks when compared
to 8 to 16 weeks. The main finding in this study was the observed positive correlation
between resting IGFBP-3 and SFMS scores at the start of the training season. The
biological significance of this relationship remains unknown. SFMS scores appeared to
increase following 8 and 16 weeks of training, while IGFBP-3 remained unchanged. This
finding suggests resting levels of IGFBP-3 may not be a sensitive marker of training
status.
Based on the findings from the present study the following recommendations
have been developed for future work. Exercise can vary widely in mode, duration and
intensity, therefore, the effects of exercise on IGF-I and IGFBP-3 have been difficult to
identify. It would be beneficial to determine the effects of different exercise variables on
both IGF-I and IGFBP-3. Since the present study evaluated swimmers age 18-24 years, it
would be interesting to see if age influences the effects of exercise training on IGF-I and
IGFBP-3. There is also a need to evaluate how different exercise variable affect IGFBP-3
proteolysis. More work is also needed to validate subjective measures of overtraining.
Finally, there is a need for research looking at the contribution of locally produced IGF-I
and how it is affected by exercise.
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Abbreviations
The following is a list of abbreviations that are used throughout this thesis.
ALS – Acid labile subunit
BMI – Body mass index
SFMS – French Society of Sports Medicine (in English)
CV – Co-efficient of Variation
ELISA - Enzyme-linked Immunosorbent assay
GH – Growth hormone
GHD – Growth hormone deficiency
GHRH – Growth hormone releasing hormone
IGF-I – Insulin-like growth factor
IGFBP-3 – Insulin-like growth factor 3
IGF-I/IGFBP-3 – Insulin-like growth factor I / Insulin-like growth factor binding protein
3 ratio
IGF-IR – Insulin-like growth factor I receptor
IR – Insulin receptor
SS – Somatostatin
WHR – Waist to hip ratio
OT – Overtraining
OTS – Overtraining syndrome
PAR-Q – Physical Activity Readiness Questionnaire
POMS – Profile of mood state
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Subject Forms
INFORMATION AND CONSENT
The utility of IGF-I and IGFBP-3 as markers of training status in elite athletes
Name                                                                              Age                          
You are invited to participate in a study involving the effects of training status on the
hormonal response to long-term training.
The purpose of this study is to determine the long-term effects of intense exercise training
on the circulating levels of the hormone insulin-like growth factor-I (IGF-I) and its
dominant binding protein, Insulin-like growth factor Binding Protein-3 (IGFBP-3). We
also want to determine if changes in IGF-I or IGFBP-3 are associated with training status
or with symptoms of overtraining. The main researcher for this study is Troy Bischler
who is a Graduate Student in the Department of Kinesiology at the University of
Lethbridge. He is supervised by Dr. Jennifer Copeland.
As a participant in this study you will be required to complete 2 medical/health
questionnaires to ensure it is safe for you to complete all the testing. The study involves
three testing phases over 4 months. The first phase will occur in September at the start of
your season, the second will occur in mid-October and the third and final phase will
occur in December at the end of this semester.
At each of these three phases the testing procedures are identical and consist of the
following:
- training status questionnaire
- 3 day food record
- 2 fasting blood samples
-heart rate and blood pressure measurement
-body composition assessment
-maximal aerobic power test
-maximal lactate
-time trial
A short description of each procedure will follow.
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TRAINING STATUS QUESTIONNAIRE
During each phase of testing you will be required to complete a standardized training
status questionnaire. The questionnaire consists of 54 straightforward “yes/no” questions.
3-DAY FOOD RECORD
For three days prior to testing you will be required to record everything you eat including
amounts, types and brands. You do not need to alter your typical eating patterns in any
way.
HEART RATE AND BLOOD PRESSURE MEASUREMENT
Both heart rate and blood pressure measurements are taken as a precaution before
exercise testing.  These measurements assist in the evaluation of an individual’s health
and fitness status. Heart rate will also be measured during the aerobic power test using a
Polar heart rate monitor. Maximal heart rate will be determined following the termination
of the maximal aerobic power test.
BODY COMPOSITION ASSESSMENT (~15 minutes)
The body composition assessment will include measurements of height, weight and
skinfolds. Skinfolds will be taken on 7 sites on your body using a skinfold caliper. The
procedure is painless and quick.
MAXIMAL AEROBIC POWER TEST (VO2MAX) (~ 30 minutes including warm-
up and cool down)
The VO2max test involves a maximal graded treadmill test. You will run at a constant
rate (typically 6-8mph), while the grade will be increased every 2 minutes until
exhaustion. During this test you will be using a mouthpiece apparatus connected to a
metabolic cart in order to measure your oxygen consumption.
MAXIMAL LACTATE MEASUREMENT (~2 minutes)
The maximal lactate measurement will be taken upon the termination of the maximal
aerobic test. A fully trained individual will take a finger prick blood sample and analyze
it for lactate concentration using a portable lactate analyzer.
RESTING BLOOD SAMPLES (~15 minutes)
A blood sample will be drawn on two mornings of each phase, for a total of 6 samples
throughout the study. Approximately 10ml of blood from a vein in your arm will be taken
by a fully trained individual. There will be strict pre-testing guidelines, which include no
eating for 12 hours prior to testing. Also, you will be asked to refrain from strenuous
physical activity for 24 hours prior to sampling.
TIME TRIAL
During a team practice prior to the beginning of each testing phase, each subject will
perform a time trial. Your dominant event will be timed and will continue to be timed for
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all three phases. The warm-up, distance, stroke, and timing procedures will be
standardized throughout the study.
POTENTIAL RISKS
Blood sampling may cause some minor discomfort. The samples will be taken under
sterile conditions by a trained individual and no complications resulting from blood
sampling have ever occurred in this laboratory. Both the time trial and the graded
treadmill test that will be used in the study require maximal effort, and as such, you may
experience some fatigue, nausea, dizziness or lightheadedness. These are normal and
expected sensations for maximal exercise and typically resolve quickly with active
recovery. The testing will be performed under the supervision of a certified Professional
Fitness and Lifestyle Consultant who is also certified in CPR and First Aid.
BENEFITS
The results of this research may identify a physiological marker to diagnose overtraining
syndrome (OTS). This would be beneficial for elite athletes and coaches as it may allow
early detection of OTS so that appropriate preventive measures can be taken.
The fitness testing in this study will also allow you to monitor your training status and
performance over the course of the semester. These test results would normally be
expensive to obtain, however, you will receive your test results at no cost. This may be
beneficial to your athletic performance.
RESULTS
Upon the completion of the study an appointment can be made with the principal
investigator to obtain and discuss your results if desired.
ANTICIPATED USE OF THE DATA
The intended use of the data collected from this study is to publish the finding of the
study. If used in publication, your identity will remain anonymous.
If you have questions about this research please contact the Principal Investigator:
Troy Bischler
Dept. of Kinesiology
University of Lethbridge
(403) 317-5073
(403) 380-1839 (f)
troy.bischler@uleth.ca
Questions regarding your rights as a participant in this research may be addressed to the
Office of Research Services, University of Lethbridge (Phone:  403-329-2747)
CONSENT
I acknowledge that:
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- Based on my knowledge there is no medical reason why I cannot perform the
testing as described
- I have completed a PAR-Q and none of my responses were “yes”
- I have reported any medication that I am taking
- the researchers have answered all my questions
- I understand the potential risks and benefits of this experiment
- my results will be provided to me upon completion of all testing, if I desire.
- all of my results, both medical and performance, will be kept strictly confidential
and if used for publication, my identity will remain anonymous
- I recognize that my involvement is voluntary and I may discontinue the testing at
any time without penalty or any negative consequences.
- I agree to inform the researcher if my health condition changes or if I begin taking
any medication while I am involved with this study.
I have read the above statements and understand the conditions of my participation in this
study.
Signature:_____________________________
Date: ________________________
Signature of researcher:_______________________
Date: ______________________
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HEALTH SCREENING FORM
The purpose of this form is to get some information about your medical and health
history.  This is to ensure that you do not have any medical or health problems that are
contraindications to the testing.
Name : _________________________________ Date:___________________
Address:
__________________________________________________________________
__________________________________________________________________
Phone (home):______________________ Medicare: _____________________
Family Physician:_____________________
__________________________________________________________________
GENERAL SCREENING
1. Have you answered "yes" to any of the questions on the PAR-Q?
2. Do you have any allergies? If so, to what?
MEDICAL HISTORY
3. Please identify if you have had any of the following health problems:
a) high blood pressure yes no
b) heart trouble yes no
c) diabetes yes no
d) asthma yes no
e) epilepsy yes no
f) thyroid disorder yes no
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g) any disease of the glands yes no
h) rheumatic fever yes no
I) arthritis, rheumatism yes no
j) kidney disease yes no
k) fainting/syncope yes no
l) other______________________
4. Have you ever had any musculoskeletal problems (injuries to bones, muscles,
joints)? If so, describe the problem. Are you currently having any musculoskeletal
problems? If so, what?
5. Have you ever been injured in an accident? If so, how?
6. Have you ever been advised for medical reasons not to participate in physical
activity? If so, when? Why?
7.     Are you taking any medications at present (including hormone contraceptives)? If
so, please provide the name of the medication.
8. Are you taking any herbal preparations or non-prescription medications not listed
above? If so, what?
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9. Do you smoke? If so, how much?
10. Is there any other medical information that you think may be important to your
participation in this study?
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TRAINING HISTORY FORM
The purpose of this form is to obtain information regarding your training history.
Name:                                                              
1. How long have you been swimming competitively?
2. On average, how many times a week do you train in the pool?
3. What is your average volume (meters) per training session?
4. On average how many time per week do you train away from the pool?
5. How many years have you been training with a varsity swim team?
6. Do you train competitively for any other sport?
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Overtraining Questionnaire
(French Society of Sports Medicine)
Sex:           M F
Date of Birth:
Are you currently doing examinations?            Y N
What is your main sport or game?
How many hours a week do you practice? 6-8 8-10 11+
If you play any other sports or games, please write them:
This month, has there been any significant event which may
have disturbed your private or professional life?  Y N
This month
1-My level of sports performance/my general form has decreased     Y N
2- I am not as attentive as before   Y N
3- My close friends think my behavior has changed   Y N
4-I have a sensation of pressure in my chest   Y N
5-My heart seems to beat faster   Y N
6-I have a lump in my throat  Y N
7-I have less of an appetite then before Y N
8-I eat more Y N
9-I do not sleep as well as before Y N
10-I drowse and yawn in the daytime Y N
11-The time between training sessions seems to me too short Y N
12-My sexual libido has decreased Y N
13-My performances are poor Y N
14-I frequently catch a cold Y N
15-I have put on weight Y N
16-I have memory problems Y N
17-I often feel tired Y N
18-I underestimate myself Y N
19-I often have cramps, muscular pain Y N
20-I suffer from headaches more frequently Y N
21-I do not feel fit Y N
22-I sometimes feel dizzy, on the point of fainting Y N
23-I do not confide in others so easily Y N
24-I often feel seedy Y N
25-I have a sore throat more often Y N
26-I feel nervous, insecure, anxious Y N
27-I do not bear training so well Y N
28-At rest, my heart rate is faster than before Y N
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29-During exercise, my heart rate is faster than before Y N
30-I often feel rotten Y N
31-I get tired more easily Y N
32-I often have digestive disorders Y N
33-I feel like staying in bed Y N
34-I am not so confident in myself Y N
35-I get injured more easily Y N
36-I have more difficulties in organizing my thoughts Y N
37-I have more difficulties in concentrating in my sports activity Y N
38-My sporting gestures are less precise, less skillful Y N
39-I have lost force and aggressiveness Y N
40-I feel as if I have no one to talk to Y N
41-I sleep longer Y N
42-I cough more often Y N
43-I do not enjoy practicing my sports as much Y N
44-I do not enjoy my leisure activities as much Y N
45-I get irritated more easily Y N
46-I am less efficient in my school or professional activity Y N
47-People around me think that I have become less available Y N
48-Training seems harder and harder Y N
49-It is my fault if my results are worse Y N
50-My legs feel heavy Y N
51-I lose my personal things more easily (wallet, keys, etc.) Y N
52-I am pessimistic, I have the blues Y N
53-I have lost weight Y N
54-My motivation, will and tenacity are weaker Y N
Put a cross to indicate where you fall in the range between these two opposite states
My physical level
Great form                                                       Bad form
I feel fatigued
More slowly                                                    More quickly
I recover from my state of tiredness
More quickly                                                  More slowly
I feel
Very relaxed                                                    Very anxious
I feel that my muscular strength has
Increased                                                         Decreased
I feel that my endurance has
Increased                                                         Decreased
Did you have any difficulties in understanding some of the questions? Y N
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Food Record
Date:                           
Name:                                      
Food/Brand     Serving size Quantity
Drink/Brand    Serving size               Quantity
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APPENDIX C
INDIVIDUAL HORMONE CONCENTRATIONS
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Table 9. Individual data for IGF-I and IGFBP-3 concentrations and IGF-I/IGFBP-3
ratio across all testing phases.
Subject Session
IGF-I
ng/mL
IGFBP-3
ng/mL
IGF-I/IGFBP-3
ng/mL
Week 0 379.3 4074 9.3
Week 8 355.7 4523.9 7.9
1
Week 16 325.5 4448.6 7.3
Week 0 230.3 3648.7 6.3
Week 8 230.6 4245.2 5.4
2
Week 16 225 3789.7 5.9
Week 0 501.6 5000.9 10
Week 8 466.3 5143.2 9.1
3
Week 16 476.4 4900.3 9.7
Week 0 353.6 4211.7 8.4
Week 8 499.8 4782.9 10.4
4
Week 16 381.1 4191.9 9.1
Week 0 269.3 3537.5 7.6
Week 8 283.8 3961.3 7.2
5
Week 16 248.8 3518.2 7.1
Week 0 207.9 4820.8 4.3
Week 8 281.1 4400.4 6.4
6
Week 16 298.7 5411.2 5.5
Week 0 299.8 5873.1 5.1
Week 8 385.5 7266.4 5.3
7
Week 16 385.4 5904.1 6.5
Week 0 338.8 4596.5 7.4
Week 8 431.4 5220.1 8.3
8
Week 16 411.8 5805.3 7.1
Week 0 298 4940.3 5.8
Week 8 300.9 5119.2 6.1
9
Week 16 247.3 4813.8 5.1
Week 0 257.3 6536.2 3.9
Week 8 271 6057.9 4.5
10
Week 16 294.7 6498.3 4.5
Week 0 547.5 6897 7.9
Week 8 534 6304.6 8.5
11
Week 16 611.1 7291.5 8.4
Week 0 360.7 4481.1 8.1
Week 8 386.4 4648.9 8.3
12
Week 16 313.2 5051.7 6.2
Week 0 336.2 ± 103 4884.8 ± 1064.86 7.0 ± 1.9
Week 8 369.9 ± 97.8 5139.5 ± 963.51 7.3 ± 1.8
Mean
SD±
Week 16 351.6 ± 110.5 5135.4 ± 1110.93 6.9 ± 1.6
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 Figure 18. Individual data for absolute change in IGF-I across time.
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Figure 19. Individual data for absolute change in IGFBP-3 across time.
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 Figure 20. Individual data for percent change in IGF-I across time.
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Figure 21. Individual data for percent change in IGFBP-3 across time.
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APPENDIX D
REFERENCE RANGES
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APPENDIX D
Reference Ranges
Hormone Range
IGF-I 49 – 550 ng/mL
IGFBP-3 1500 – 5580 ng/mL
Diagnostic Systems Laboratories Inc., TX., USA
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APPENDIX E
IGF-I AND IGFBP-3 ASSAY PROCEDURES
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APPENDIX E
Hormone Assay Procedures
Table 10. Enzyme-linked Immunosorbent Assay procedures for analysis of serum
IGF-I and IGFBP-3
IGF-I IGFBP-3
1. Mark microtitration strips to be used 1. Mark microtitration strips to be used
2. Pipet 20uL of each standard, control
and pretreated unknown to appropriate
wells.
2. Pipet 25uL of each standard, control and
pretreated unknown to appropriate wells.
3. Add 100uL of the assay buffer to each
well using a semi-automatic dispenser.
3. Add 50 uL of the assay buffer to each
well using a semi-automatic dispenser.
4. Incubate the wells, shaking at a fast
speed (500-600rpm) on an orbital
microplate shaker for 2 hours at room
temperature.
4. Incubate the wells, shaking at a fast
speed (500-600rpm) on an orbital
microplate shaker for 2 hours at room
temperature.
 5. Aspirate and wash each well five times
with the wash solution using an automatic
microplate washer.
5. Aspirate and wash each well five times
with the wash solution using an automatic
microplate washer.
6. Prepare the antibody-enzyme conjugate
solution.
6. Prepare the antibody-enzyme conjugate
solution.
7. Add 100uL of the antibody-enzyme
conjugate solution to each well using a
semi-automatic dispenser.
7. Add 100uL of the antibody-enzyme
conjugate solution to each well using a
semi-automatic dispenser.
8. Incubate the wells, shaking at a fast
speed (500-600 rpm) for 30 minutes.
8. Incubate the wells, shaking at a fast
speed (500-600 rpm) for 1 hour.
 9. Aspirate and wash each well five times
with the wash solution using an automatic
microplate washer.
 9. Aspirate and wash each well five times
with the wash solution using an automatic
microplate washer.
10. Add 100uL of the TMB chromogen
solution to each well using a semi-
automatic dispenser.
10. Add 100uL of the TMB chromogen
solution to each well using a semi-
automatic dispenser.
11. Incubate the wells, shaking at a fast
speed (500-600 rpm) for 10 minutes.
11. Incubate the wells, shaking at a fast
speed (500-600 rpm) for 10 minutes.
12. Add 100uL of the stopping solution to
each well using a semi-automatic
dispenser.
12. Add 100uL of the stopping solution to
each well using a semi-automatic
dispenser.
13. Read the absorbance of the solution in
the wells within 30 minutes, using a
microplate reader set to 450nm.
13. Read the absorbance of the solution in
the wells within 30 minutes, using a
microplate reader set to 450nm.
